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A B S T R A C T
Background
Erosive lichen planus (ELP) affecting mucosal surfaces is a chronic autoimmune disease of unknown aetiology. It is often more painful
and debilitating than the non-erosive types of lichen planus. Treatment of erosive lichen planus is difficult and aimed at palliation
rather than cure. Several topical and systemic agents have been used with varying results. Another Cochrane review has already assessed
interventions for lichen planus affecting the mouth.
Objectives
To assess the effects of interventions in the treatment of erosive lichen planus affecting the oral, anogenital, and oesophageal regions.
Search methods
We searched the following databases up to September 2009: the Cochrane Skin Group Specialised Register, the Cochrane Central
Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE (from 2005), EMBASE (from 2007), and LILACS
(from 1982). We also searched reference lists of articles and online trials registries for ongoing trials.
Selection criteria
We considered all randomised controlled trials (RCTs) that evaluated the effectiveness of any topical or systemic interventions for ELP
affecting either the mouth, genital region, or both areas, in participants of any age, gender, or race.
Data collection and analysis
The primary outcome measures were as follows:
(a) Pain reduction using a visual analogue scale rated by participants;
(b) Physician Global Assessment; and
(c) Participant global self-assessment.
Changes in scores at the end of therapy compared with baseline were analysed.
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Main results
Fifteen RCTs were included, giving a total of 473 participants with ELP (study sizes ranged between 8-94). All studies involved oral
sites only. Six studies included participants with non-erosive lichen planus but only the erosive subgroup was included for intended
subgroup analysis. We were unable to pool data from any of the nine studies with only ELP participants or any of the six studies with
the ELP subgroup, due to small numbers and the heterogeneity of the interventions, design methods, and outcome variables between
studies.
One study involving 50 participants found that 0.025% clobetasol propionate administered as liquid microspheres significantly reduced
pain compared to ointment (Mean difference (MD) -18.30, 95% confidence interval (CI) -28.57 to -8.03), but outcome data was
only available in 45 participants (high risk of performance bias for blinding of participants, low/unclear risk of bias overall). However,
in another study, a significant difference in pain was seen in the small subgroup of 11 ELP participants, favouring ciclosporin solution
over 0.1% triamcinolone acetonide in orabase (MD -1.40, 95% CI -1.86 to -0.94) (high risk of performance and detection bias due to
likely lack of blinding, low/unclear risk of bias overall). Aloe vera gel was 6 times more likely to result in at least a 50% improvement
in pain symptoms compared to placebo in a study involving 45 ELP participants (Risk ratio (RR) 6.16, 95% CI 2.35 to 16.13) (low
risk of bias overall). No significant difference was seen in Physician Global Assessment in these three studies.
In a small single study involving 20 ELP participants, 1% pimecrolimus creamwas 7 times more likely to result in a strong improvement
as rated by the Physician Global Assessment when compared to vehicle cream (RR 7.00, 95%CI 1.04 to 46.95) (low risk of bias overall).
In a study involving a small subgroup of 8 ELP participants, a significant difference was seen for an improvement in the severity of the
disease as rated by the Physician Global Assessment, in favour of the ciclosporin group when compared to the vehicle (MD -1.40, 95%
CI -1.86 to -0.94) (unclear risk of selection bias for allocation concealment, overall risk of bias low).
No statistically significant benefits were shown for topical tacrolimus or fluticasone spray in two separate studies of 29 and 44 participants
respectively.
There is no overwhelming evidence for the efficacy of a single treatment, including topical steroids, which are the widely accepted first-
line therapy for ELP. Several side-effects were reported, but none were serious. With topical corticosteroids, the main side-effects were
oral candidiasis and dyspepsia.
Authors’ conclusions
This review suggests that there is only weak evidence for the effectiveness of any of the treatments for oral ELP, whilst no evidence was
found for genital ELP. More RCTs on a larger scale are needed in the oral and genital ELP populations. We suggest that future studies
should have standardised outcome variables that are clinically important to affected individuals. We recommend the measurement of
a clinical severity score and a participant-rated symptom score using agreed and validated severity scoring tools. We also recommend
the development of a validated combined severity scoring tool for both oral and genital populations.
P L A I N L A N G U A G E S U M M A R Y
Treatments for erosive lichen planus affecting mucosal sites
Erosive lichen planus (ELP) is a condition that affects the mouth, oesophagus (food pipe or gullet), and anogenital region. It is caused
by an over-active immune system. It is often more painful and debilitating than the non-erosive types of lichen planus. Depending on
the site involved, affected individuals may experience pain, and difficulty eating; passing urine; or having sexual intercourse. Treatment
is difficult and aimed at controlling symptoms, rather than cure. Several creams and tablets have been used with varying results.
This review looked at the effectiveness of treatments for ELP and included 15 studies, with 473 participants with ELP. All involved oral,
but not genital, disease. Many studies were excluded either because they were not randomised controlled trials (where participants are
divided into two groups at random) or because they recruited participants with all types of lichen planus, rather than just the erosive
subtypes. All of these studies recruited small numbers of participants (12 to 94) and used a variety of different assessment methods and
timings; hence, it was not possible to combine or compare results between studies directly.
We found only weak evidence for the effectiveness of any of the treatments for oral ELP. None of the studies involved genital or
oesophageal disease; hence, no evidence was found for the treatment of these conditions. One small study found that 0.025% clobetasol
propionate (a very potent topical steroid) administered as a spray significantly reduced pain when compared to ointment. In another
study, a significant difference in pain was seen in the small subgroup of 11 ELP participants, favouring ciclosporin solution over 0.1%
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triamcinolone acetonide in orabase (a potent topical steroid). In a study involving 45 ELP participants, aloe vera gel was 6 times more
likely to result in at least a 50% improvement in pain symptoms compared to placebo. In a study involving a small subgroup of 8 ELP
participants, a significant difference was seen for an improvement in the severity of the disease in favour of the ciclosporin group when
compared to the vehicle.
Several side-effects were reported, but none were serious. With topical corticosteroids, the main side-effects were oral candida (yeast)
infection and pain or discomfort in the upper abdomen. Temporary burning was a common side-effect reported with tacrolimus 0.1%
ointment and pimecrolimus 0.1% cream.
Overall, there was no overwhelming evidence for the effectiveness of any single treatment, including topical steroids, which are the
widely accepted first-line therapy for ELP. This was mainly due to the lack of good-quality, well-conducted trials and small participant
numbers. Another Cochrane review has already assessed interventions for lichen planus affecting the mouth.
B A C K G R O U N D
Description of the condition
Definition
Lichen planus (LP) is an inflammatory condition that affects the
skin and the squamous epithelium of mucosal surfaces lining the
mouth, ears, eyes, and nose as well as the gastrointestinal and
anogenital tracts. There are predominantly two patterns of in-
flammation described: the plaque (raised) type and the erosive
(raw) type, although bullous, blistering, or hypertrophic (thick-
ened) types also occasionally occur.
The plaque type occurs most commonly and is estimated to af-
fect up to 2% of the population (Boyd 1991; Carrozzo 2008). It
presents as purple raised areas with a surface made of a lacy, white
network known as Wickham’s striae. The lesions are predomi-
nantly distributed on the inner aspect of the wrists and ankles, al-
though they may occur on any body surface lined with squamous
epithelium (Boyd 1991; Breathnach 2004). Plaques of LP are of-
ten itchy, and, without treatment, they may take up to two years
to settle. Occasionally the lesions are present without many symp-
toms and may remain for years (Boyd 1991; Breathnach 2004).
In contrast, erosive lichen planus (ELP) is a very painful and de-
bilitating condition. The prevalence of ELP is unknown. It occurs
predominantly, but not exclusively, on the mucosal surfaces of the
mouth and genitals (oral, vulval, vaginal, andpenile lichenplanus).
Other less commonly affected sites include the eyes (Neumann
1993) and oesophagus (Abraham 2000). There may also be blad-
der, nasal, laryngeal, gastric, and anal involvement (Eisen 1999).
Erosive lichen planus can be accompanied by classical cutaneous
LP or other forms of mucosal LP, namely reticular (lacy), papular
(solid, raised bumps less than 5 mm in diameter), plaque (raised),
atrophic (thinned), and bullous (blisters) variants.
A severe variant of ELP in women involving both the genital and
oral mucosa was described by Pelisse et al (Pelisse 1982; Pelisse
1989) as the vulvovaginal-gingival (VVG) syndrome. This syn-
drome is a triad of (erosive or desquamative) vulvitis, vaginitis,
and gingivitis. The equivalent condition in men is known as the
peno-gingival (PG) syndrome, described by Cribier et al in 1993
(Cribier 1993).
Since ELP can affect different body sites, a number of health-
care specialists are involved in managing affected individuals: oral
medicine physicians; dermatologists; gynaecologists; and, if the
oesophagus is involved, gastroenterologists.
Impact of Erosive Lichen Planus
Erosive lichen planus is a chronic, painful condition, which is of-
ten difficult to treat. The psychological, emotional, and physi-
cal distress associated with ELP affecting any mucosal site can be
significant with affected individuals suffering low moods with or
without treatment. This has economic consequences both for the
people affected and the health system. Affected individuals fre-
quently attend hospital complaining of pain and loss of function,
which interferes with their personal and working life. It is impor-
tant that healthcare providers are able to identify and treat any
psychological issues arising as a result of ELP. Engaging a coun-
sellor, as part of the multidisciplinary team, may be beneficial in
these instances.
Symptoms vary according to the site involved. Individuals with
erosive oral lichen planus (OLP) present with pain and difficulty
eating. With milder disease the discomfort is mainly from spicy or
acidic foods, and fizzy drinks. With more extensive disease there
are painful, persistent erosions on the gingivae (gums), and ulcers
on the buccal (inside of cheek), tongue, and labial (lip) mucosae.
Difficulty eating results in weight loss and nutritional deficiencies,
such as iron deficiency (Eisen 1999). Painful erosions lead to sub-
optimal dental hygiene and increased tooth decay.
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The areas commonly affected in the vulva are the labia minora
(inner lips), introitus (entrance to the vagina), and vaginal vault
(arched roof of the vaginal cavity). The affected areas may be
erythematous, atrophic, and eroded. This makes them tender and
extremely painful to light touch, such as pressure from sitting and
walking. Individuals complain of pain and stinging on passing
urine, and they are sometimes only able to urinate in comfort by
sitting or standing in water in the bath or shower. Anatomical
alterations, such as fusion of the labia minora, may cause impaired
urine flow.
Sexual intercourse can be impossible due to pain and anatomical
changes. In addition, the eroded vagina bleeds easily on contact;
hence, postcoital bleeding (bleeding following sexual intercourse)
is typical. Inflammation higher up in the vagina (desquamative
vaginitis) presents as a yellow discharge. With ongoing inflam-
mation, the clitoral hood typically disappears, the labia minora
adheres to the labia majora, and the introitus closes over. Scar-
ring in the vagina leads to narrowing and a fibrosed vaginal vault,
making cervical smears either impossible or difficult. In addition
to organic dysfunction, the architectural disfigurement will cause
psychological distress.
In men, ELP characteristically affects the glans penis, producing
similar painful, tender, red and raw lesions, and reduced sexual
function.
Risk of Malignant Transformation
Lesions of LP are thought to have an increased risk of develop-
ment of malignancies; therefore, it is mandatory to follow up these
people. TheWorldHealthOrganization (WHO) criteria (Kramer
1978) states that oral LP is a condition that predisposes to ma-
lignant transformation. Approximately 1% to 5% of oral LP le-
sions will undergo malignant changes into squamous cell carci-
noma (SCC) of the mouth (Gandolfo 2004; Holmstrup 1988;
Lo Muzio 1998; Silverman 1985). Approximately 1% to 3% of
vulval LP lesions develop into SCC (Cooper 2006; Lewis 1994)
and a small, but unknown, percentage of penile LP lesions trans-
form into SCC (Bain 1989; Leal-Khouri 1994). High-risk factors
for malignant transformation in oral LP include smoking; exces-
sive alcohol ingestion; erosive or atrophic clinical types; presence
of erythroplakic lesions (reddened patches with a velvety surface
found in the mouth); and sites involving the tongue, gingival, or
buccal mucosa (Scully 2008). No risk factors are known for pro-
gression of vulval LP into carcinoma of the vulva. It is unknown
if early treatment of ELP reduces the risk of malignancy.
Description of the intervention
Themanagement of ELP is challenging, and there is no clear agree-
ment with respect to the best first-line treatment in oral or genital
disease. Indeed, neither is there agreement as to whether first-line
therapy should be the same at both sites. People often respond
poorly to the available treatments. The treatments for both oral
and genital ELP are similar, but they have never previously been
considered together in a systematic review. Clinical experience of
combined oral medicine and dermatology clinics suggests that ef-
fective treatment for ELP in the oral region is likely to be beneficial
in the genital region and vice versa. ELP is a chronic autoimmune
condition with T-cell mediated immunity playing a major role;
hence, most interventions are targeted at the immune system and
increasingly at treatments to reduce T-cell activity.
Most clinicians use topical or intralesional steroids as first-line
treatment for both oral and genital ELP. There is no clinical agree-
ment for second-line therapy, although a short course of sys-
temic steroids may be administered for rapid control of symp-
toms. Steroid-sparing agents, such as azathioprine, methotrex-
ate (Jang 2008), or ciclosporin, can be used. Topical or sys-
temic retinoids, anti-malarials, dapsone, psoralen + UVA treat-
ment (PUVA) (Lundquist 1995), thalidomide (Camisa 2000),
aloe vera gel (Rajar 2008), topical tacrolimus (Kaliakatsou 2002),
or topical rapamycin (Soria 2009) may be considered in refractory
cases. Surgicalmanagement, such as carbon dioxide laser, cryother-
apy, and excision, is not recommended due to the possibility of
triggering lesions (Koebner’s phenomenon) and recurrence of the
inflammatory condition.
In recent years, reports have been published on the use of biolog-
ical therapies, such as efalizumab (Cheng 2006; Heffernan 2007)
and alefacept (Chang 2008). However, the European Medicines
Agency (EMEA), which is the EuropeanUnion (EU) body respon-
sible for monitoring the safety of medicines, has recommended the
suspension of marketing authorisation for efalizumab (Raptiva)
over possible links between the drug and progressive multifocal
leukencephalopathy (PML). A recent small case series comparing
alefacept to placebo reported that alefacept may confer a moderate
therapeutic response in ELP (Chang 2008). Alefacept is approved
by the US Food and Drugs Administration (FDA) for the treat-
ment of psoriasis, but it is not approved in the UK.
How the intervention might work
The exact cause of ELP is poorly understood. It is thought to be
autoimmune and idiopathic inmost cases. Studies suggest that up-
regulation of T-cell-mediated immunity plays a major role (Baldo
2010; Boyd 1991; Porter 1997; Scully 2008; Thornhill 2001), re-
sulting in apoptosis of epithelial cells and chronic inflammation.
Most interventions that are reported to improve ELP, as described
above, have immunomodulatory or immunosuppressive effects.
This may explain why efalizumab has been beneficial in some cases
(Cheng 2006; Heffernan 2007).
Why it is important to do this review
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For years, the acceptedfirst-line therapy for ELPhas been the use of
ultra-potent topical steroids (Carbone 2009).Whilst there appears
to be symptomatic improvement for some people (Cooper 2006),
the condition rarely goes into complete remission. In addition
to assessing whether treatments can improve symptoms in the
short-term, it is important to assess the long-term management
of ELP. This is because it is a chronic condition and long-term
use of some treatments, like potent topical steroids, can have side-
effects, such as skin thinning. There is poor consensus for a second-
line therapy in individuals who have failed to adequately respond
to topical steroids. This has resulted in the emergence of newer
therapies, such as tacrolimus (Lozada-Nur 2006) and efalizumab
(Heffernan 2007), in recent years. In such a painful and disabling
condition, it is important that affected individuals are given the
most therapeutically efficacious treatments.
ACochrane reviewupdate on ’Interventions for oral lichen planus’
has recently been published (Thongprasom 2011). The authors
identified 28 randomised controlled trials (RCTs); however, due
to the wide range of interventions compared, there is insufficient
evidence to support the effectiveness of any specific treatment for
oral LP as being superior. Another systematic review focusing on
treatments used in oral LP (Zakrzewska 2005) concluded that due
to small study sizes, lack of standardised outcome measures, and
high likelihood of publication bias, the results are not reliable.
Our review is different to these because it is not restricted to oral
disease and focuses only on the erosive type of LP. Because ELP is
a systemic disease affecting all mucosal surfaces, this review looks
at not only oral sites, but all mucosal sites. Individuals with ELP
affecting multiple mucosal sites represent a particularly challeng-
ing subset of individuals to treat.
O B J E C T I V E S
To assess the effects of interventions in the treatment of erosive
lichen planus affecting the oral, anogenital, and oesophageal re-
gions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials (RCTs) that eval-
uated the effectiveness of either topical or systemic interventions
for ELP affecting either the mouth, genital region, or both areas.
We included cross-over studies, but not split body-part designs
because it is not possible to apply two topical treatments to either
half of the oral mucosa or vulva without cross-contamination.
Types of participants
We included any individual of any age, gender, or race who had
been diagnosed by either a dermatologist, oral medicine physician,
genitourinary physician, or a gynaecologist as having ELP affect-
ing the mouth, oesophagus, and/or anogenital regions. A clinical
diagnosis stating specifically ’erosive lichen planus’ alone from an
experienced physician was considered diagnostically sufficient. A
histological diagnosis was not considered necessary since for ero-
sive disease there are no specific histological features. Biopsy often
serves to exclude dysplasia, rather than confirm the diagnosis of
ELP.
We excluded any studies including individuals with idiopathic,
plaque-like LP (non-erosive); individuals with lichenoid drug
eruptions; or individuals showing evidence of dysplasia.
Types of interventions
We included all types of interventions, including topical treat-
ments (such as potent topical steroids, ciclosporin, tacrolimus, and
retinoids), oral medications (such as prednisolone, azathioprine,
methotrexate, retinoids, ciclosporin, and mycophenolate), anti-
malarials, biologics, phototherapy, and surgical management.
We also included trials of different doses of the same interven-
tion, comparison trials between different interventions, interven-
tion versus placebo trials, intervention versus ’no treatment’ trials,
and cross-over studies. We also explored intervention strategies,
such as intermittent therapies that are designed tomaintain remis-
sion and prevent further flares.
Types of outcome measures
Most outcome measures in ELP are assessed clinically. This in-
cludes a scale-rating of improvement of clinical signs (e.g. ery-
thema, ulceration) by investigators and symptoms (e.g. pain, dis-
comfort) by participants as well as restoration of normal functions,
such as sexual activity and a varied diet (ability to eat), as reported
by participants.
Primary outcomes
(a) Pain reduction using a visual analogue scale rated by partici-
pants (e.g. 0 to 10).
(b) Physician Global Assessment (e.g. five-point).
(c) Participant global self-assessment.
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Secondary outcomes
(a) Complete clinical response defined as the percentage of partic-
ipants with complete resolution of clinical signs or symptoms.
(b) Partial response defined as the percentage of participants with
at least 50% improvement.
A partial clinical response was defined as at least 50% improve-
ment, mainly to test the literature. In practice, affected individuals
would usually report that they are “better”, “worse”, or “the same”.
(c) Reduction in severity of flares.
(d) Reduction in number of flares.
(e) Relapse rate when medications are stopped or reduced.
(f ) Dermatology quality of life measures.
(g)Restorationof sexual activity (ofmost relevance to genital sites).
(h) Eating a normally varied diet (most relevant to oral involve-
ment).
(i) Side-effects reported.
(j) Reduction in target/mean lesion size (for oral lesions).
Timing of outcome assessment
Where possible, we recorded outcomes in the short-term (less than
six months) and long-term (six months or more) from the begin-
ning of treatment.
Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, and in progress).
Electronic searches
We searched the following databases up to 7 September 2009:
• the Cochrane Skin Group Specialised Register using the
following search terms: ((eros* or vulva* or oral or ulcerated or
mucos*) and (lichen and planus)) or (lichen and planus);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library using the search strategy
in Appendix 1;
• MEDLINE (from 2005) using the search strategy in
Appendix 2;
• EMBASE (from 2007) using the search strategy in
Appendix 3; and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the search strategy in
Appendix 4.
TheUK andUSCochrane Centres (CCs) have an ongoing project
to systematically search MEDLINE and EMBASE for reports of
trials that are then included in the Cochrane Register of Con-
trolled Trials. Searches have been undertaken for this review by
the Cochrane Skin Group to cover the years that have not been
searched by the UK and US CCs.
A final prepublication search for this review was undertaken on
17 August 2011. Although it has not been possible to incorporate
RCTs identified through this search within this review, relevant
references are listed under Studies awaiting classification. They
will be incorporated into the next update of the review.
Ongoing trials
We searched for ongoing trials in the following registers using the
term ’erosive lichen planus’ on 26 June 2011:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).
• The Ongoing Skin Trials Register (www.nottingham.ac.uk/
ongoingskintrials).
Searching other resources
Unpublished and Grey literature
We attempted to obtain unpublished trials through correspon-
dence with authors.
Reference lists
We examined reference lists of the relevant trials and reviews iden-
tified.
Correspondence
We wrote to trial authors to clarify trial details.
Language
We did not impose language restrictions when searching for trials,
and we sought translations where necessary.
Adverse Effects
We searched the included studies for reports of adverse effects.
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Data collection and analysis
Selection of studies
Two authors (SCh and RM) independently reviewed the titles,
abstracts, and key words of all records retrieved in the searches.
SCh and RM obtained the full text of all relevant, or possibly
relevant, references.
Data extraction and management
We designed a paper data extraction form according to the pre-
defined selection criteria. Two authors (SCh and RM) indepen-
dently confirmed eligibility, assessed quality, and extracted data.
Differences in opinion were resolved by discussion with a third
author until a consensus was met.We kept logs of excluded studies
with reasons for exclusion. One author (JL-B) checked and en-
tered data into Review Manager.
Assessment of risk of bias in included studies
Two authors (SCh and RM) independently assessed the quality of
the included studies by using the new features of ReviewManager,
as described in Table 8.5c of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011), to assess the risk of
bias (selection bias, performance bias, attrition bias, and detection
bias).
Measures of treatment effect
We presented binary data as risk ratios (RR) with 95% confidence
intervals (CI). We presented continuous data as mean differences
(MD) with 95% CIs.
Unit of analysis issues
There were no unit of analysis issues since all studies randomised
whole participants. For studies that used a cross-over trial design,
we presented the results based on those reported in the original
paper since we were unable to estimate appropriate statistics that
allowed for the design (for example, conditional odds ratios).
Dealing with missing data
We contacted the trial authors to try to obtain trial-level data not
originally reported, and we received replies from two authors. As
we did not expect to have access to individual participant-level
data, we did not perform any imputation procedures.
Assessment of heterogeneity
We planned to quantify statistical heterogeneity using I² statistic;
however, no pooling of studies was performed due to the limited
numbers of studies and clinical heterogeneity between the trials.
Assessment of reporting biases
We planned to generate a funnel plot to assess publication bias;
however, this was not possible due to insufficient studies.
Data synthesis
Due to the limited number of studies and heterogeneity of in-
terventions, we were unable to perform meta-analyses but, where
possible, we have presented the results from individual studies us-
ing forest plots.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis to explore treatment
effect differences betweenELPof themouth and genitals; however,
we were unable to do this since we did not identify any eligible
studies of genital ELP.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Please see Table 1 (’Summary of Included Studies’) for a simple
summary of the data in the ’Characteristics of included studies’
tables.
Results of the search
The database search identified 220 papers initially. Fifty-one full
text papers were retrieved, of which 15 were included (Campisi
2004; Carbone 2009; Choonhakarn 2008; Conrotto 2006; Eisen
1990; Hegarty 2002; Lin 2005; Malhotra 2008; Passeron 2007;
Radfar 2008; Sardella 1998; Swift 2005; Volz 2008; Voute 1993;
Yoke 2006).
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Included studies
The 15 included RCTs had a total of 667 participants with LP
affecting mucosal sites, of which 473 participants had the erosive
subtype of LP. Please see the ’Characteristics of included studies’
tables for detailed information about all of the included studies,
which are summarised as follows.
Design
Fourteen studies were conducted as a parallel design, and 1 study
was conducted as a cross-over design (Hegarty 2002).
Sample sizes
The number of participants in each individual study ranged from
12 to 139. Table 1 summarises the range of therapies. All of the
included studies recruited participants with only oral - not genital
- disease. Six studies (Choonhakarn 2008; Eisen 1990; Malhotra
2008; Sardella 1998; Voute 1993; Yoke 2006) included partici-
pants with non-erosive LP. The breakdown of data on the ELP
subset was, either, already published or obtained directly from the
authors on request; hence, these studies were included, but con-
sidered separately. This brings the total number of participants
with ELP to 473 (individual studies ranged between 8 to 94 par-
ticipants).
Setting
All included studies were performed in secondary care. One study
(Yoke 2006) was a multicentre study.
Participants
The diagnosis of ELP was confirmed clinically in all studies
and histologically in all but one (Malhotra 2008). Three studies
(Carbone 2009; Conrotto 2006; Sardella 1998) were based on the
WHO 1978 criteria for oral precancerous lesions (Kramer 1978).
Interventions
Multiple therapies were considered, as shown in Table 1.
Six studies compared an active topical agent (aloe vera gel, ci-
closporin rinse, fluocinonide in adhesive base, and 1% pime-
crolimus cream in three studies) to placebo.
Two studies compared topical clobetasol propionate, currently the
most frequently used treatment in clinical practice, either in a
different delivery vehicle (lipid-loaded microspheres versus oint-
ment) or a different concentration (0.025% versus 0.05%).
Seven studies compared an active agent against another active
agent head-to-head. These therapies can be broadly divided into
three groups:
(i) topical steroids - clobetasol propionate ointment and gel, triam-
cinolone acetonide paste, fluticasone propionate spray, betametha-
sone sodium phosphate mouthwash;
(ii) other topical therapy - tacrolimus ointment, ciclosporin gel
and solution, mesalazine gel; or
(iii) systemic therapy - betamethasone oralmini-pulse therapy, root
of (radix) tripterygium hypoglaucum tablet (THT), tripterygium
glucosides tablet (TGT).
Outcomes
Primary outcomes
There was no consensus in the included studies regarding the tools
used for assessing the primary outcomes (see Table 2).
(a) Pain reduction using a visual analogue scale rated by
participants
Ten studies measured participant-reported symptoms using a vi-
sual analogue scale of 0 to 10 or 0 to 100 (Campisi 2004; Carbone
2009; Choonhakarn 2008; Conrotto 2006;Hegarty 2002; Radfar
2008; Sardella 1998; Swift 2005; Volz 2008; Yoke 2006). Voute
1993 also measured using a visual analogue scale (VAS), but the
scale was not specified. Two studies measured this using different
tools: Passeron 2007 used a visual scale of 0 to 4, and Eisen 1990
measured global symptom scores on an ordinal scale of 0 to 3. Two
studies (Lin 2005; Malhotra 2008) did not measure participant-
reported symptoms at all.
(b) Physician Global Assessment (e.g. five-point)
All but 2 studies (Radfar 2008; Sardella 1998) measured physician
global assessment, but using several different methods: 6 studies
(Campisi 2004; Carbone 2009; Choonhakarn 2008; Conrotto
2006; Hegarty 2002; Yoke 2006) used the clinical grading by
Thongprasom 1992 consisting of a 6-point ordinal scale from 0
(no lesions) to 5 (white striae with erosive area more than 1 cm²),
6 used their own clinical grading scale (Eisen 1990; Lin 2005;
Malhotra 2008; Passeron 2007; Volz 2008; Voute 1993), whilst
Swift 2005 measured clinical score as weighted sums of ulceration
mm², erythema mm², and reticulation mm².
(c) Participant global self-assessment
One study asked participants about their subjective evaluation of
the efficacy of treatment at the end of the study (Passeron 2007)
on a five-point ordinal scale (worse, no effect, mild, moderate, or
important improvement).
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Secondary outcomes
The majority of the secondary outcomes specified in this review
were not assessed in the included studies: e.g. (c) Reduction in
severity of flares, (d) Reduction in number of flares, (g) Restoration of
sexual activity (of most relevance to genital sites), and (h) Eating a
normally varied diet (most relevant to oral involvement).
(a) Complete clinical response defined as the percentage of
participants with complete resolution of clinical signs or
symptoms
Volz 2008 reported complete clinical response.
(b) Partial response defined as the percentage of participants
with at least 50% improvement
A partial clinical response was defined as at least 50% improve-
ment, mainly to test the literature. In practice, affected individuals
would usually report that they were ’better’, ’worse’, or ’the same’.
Carbone 2009, Conrotto 2006, Hegarty 2002, Lin 2005,
Choonhakarn 2008, and Voute 1993 reported partial response.
(e) Relapse rate when medications are stopped or reduced
Passeron 2007 and Conrotto 2006 reported relapse rate when
medication was stopped.
(f) Dermatology quality of life measures
Only one study measured quality of life (Hegarty 2002) using
the Oral Health Impact Profile (OHIP) and Oral Health QoL
questionnaires (OHQOL). These two quality of life measurement
tools are not specific to vulval disease.
(i) Side-effects reported
All of the included studies measured side-effects.
(j) Reduction in target/mean lesion size (for oral lesions)
Two studies reported a reduction in target/mean lesion size
(Hegarty 2002; Radfar 2008).
Excluded studies
We excluded 36 studies, and the reasons for exclusion are listed in
the ’Characteristics of excluded studies’ tables.
Fifteen studies were excluded because initially they appeared to be
RCTs, but on reading the full text, they were not RCTs.
Thirteen studies were not ELP, or recruited predominantly non-
erosive subtypes of mucosal LP (e.g. reticulate LP).
The authors of a further three papers were contacted for further
information on breakdown of data for the erosive subtype, but no
response was received. Of these three, one study recruited partici-
pants with vulval LP (Rajar 2008). This was the only study look-
ing at vulval LP, but only 82% of subjects had erosive lesions. We
excluded this study because no data for the erosive subtype was
available. In addition, details of the randomisation method were
not available.
The remaining five studies were excluded for the following reasons:
· one was a split body-part design (Xia 2006);
· one was a review (Lehman 2009);
· one included participants with dysplasia (Scardina 2006);
· one trial compared circuminoids as an adjunct to oral steroids
(Chainani-Wu 2007); and
· one trial investigating the use of ignatia, a homeopathic
remedy for hysteria, only included participants with “the mind
and general symptom of ignatia” (Mousavi 2009).
Studies awaiting classification
As a result of the final search, we have identified six potential
trials, which are detailed in the ’Characteristics of studies awaiting
classification’ tables. These will be dealt with in a future update of
this review.
Ongoing Studies
We found four ongoing studies when we ran our pre-publication
search, details of which are in the ’Characteristics of ongoing
studies’ tables. These will be dealt with in a future update of this
review.
Risk of bias in included studies
We independently analysed the risk of bias for each individual
study. This is discussed in detail in the ’Characteristics of included
studies’ tables and summarised in Figure 1 and Figure 2.
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Figure 1. ’Risk of bias’ graph - review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary - review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Allocation
The randomisationmethodwas stated in all but two studies (Voute
1993; Yoke 2006), which were rated as unclear. The methods used
included random number tables (Carbone 2009; Choonhakarn
2008; Conrotto 2006; Eisen 1990; Hegarty 2002; Lin 2005;
Malhotra 2008; Radfar 2008; Sardella 1998; Swift 2005), block
randomisation (Campisi 2004; Passeron 2007), and an automated
system of assigning randomisation numbers (Volz 2008).
Allocation concealment was stated in seven studies via a central
office pharmacy and was, therefore, judged at low risk of bias
(Choonhakarn 2008; Conrotto 2006; Radfar 2008; Swift 2005;
Volz 2008; Voute 1993; Yoke 2006).
Blinding
Campisi 2004, Hegarty 2002, Malhotra 2008, and Yoke 2006
were not blinded to participants for practical reasons relating to
themode of therapy administration or use of different bases. It was
unclear if Lin 2005, Passeron 2007, and Voute 1993 were blinded
to participants.
Ten studies were blinded to clinicians. It was unclear if Lin 2005,
Malhotra 2008, Passeron 2007, Voute 1993, and Yoke 2006 were
blinded.
Incomplete outcome data
Of the nine studieswhich recruited only ELPparticipants, six stud-
ies performed intention-to-treat (ITT) analyses (Hegarty 2002;
Lin 2005; Passeron 2007; Swift 2005; Volz 2008; Radfar 2008),
of which one study (Swift 2005) had two losses early on that were
replaced before the study commenced. These six studies were rated
as at low risk of bias for this domain. Three studies with losses did
not appear to be ITT (Campisi 2004; Carbone 2009; Conrotto
2006) and were, thus, rated as at unclear risk of bias.
Of the six studies that recruited both ELP and non-ELP partic-
ipants, five performed ITT analyses (Choonhakarn 2008; Eisen
1990; Sardella 1998; Voute 1993; Yoke 2006) and were rated as at
low risk of bias for this domain. One study (Malhotra 2008) was
rated as at high risk of bias for this domain because there were three
losses to follow-up that were not included in the final analysis.
Selective reporting
Hegarty 2002 did not report any data on clinical score 0 to 5
(Thongprasom 1992), even though this was mentioned in their
methods section “clinician (objective) assessment”, so it was the
only study rated as at high risk of bias for this domain.
Other potential sources of bias
We did not find any other potential sources of bias in any of the
15 included trials.
Effects of interventions
Primary outcomes
(a) Pain reduction using a visual analogue scale (VAS) rated
by participants
All of the studies reported pain as a pain score, rather than a reduc-
tion in pain. Additionally, the outcome relates to the pain score
at follow-up, and baseline scores were not taken into account for
this review since using randomisation methods should eliminate
differences at baseline between the two interventions groups.
In the Swift 2005 study (n = 20), which compared 1% pime-
crolimus cream against placebo for 4 weeks, no significant reduc-
tion in pain was seen (MD -3.30, 95% CI -20.22 to 13.62) (see
Analysis 1.1).
In the Passeron 2007 study (n = 12), which compared 1% pime-
crolimus cream against placebo, no significant reduction in basal
pain (MD0.16, 95%CI -0.86 to 1.18) or pain when feeding (MD
0.34, 95% CI -1.36 to 2.04) was seen (see Analysis 1.1).
In the Campisi 2004 study (n = 50 recruited, but follow-up data
was only available in 45 participants), 0.025% clobetasol propi-
onate lipid-loaded microspheres were found to significantly re-
duce pain when compared to a conventional formulation (0.025%
lipophilic ointment in the hydrophilic phase) (MD -18.30, 95%
CI -28.57 to -8.03) (see Analysis 2.1). However, in the Sardella
1998 study (n = 12), no significant reduction in pain was seen for
0.05% clobetasol propionate when compared to 5% mesalazine
gel (MD -0.83, 95% CI -4.12 to 2.46) (see Analysis 2.1). Addi-
tionally, no significant difference in pain was seen when 0.025%
was compared to 0.05% clobetasol propionate in the Carbone
2009 study (n = 30) when comparing the mean scores (MD -0.26,
95% CI -1.42 to 0.90) (see Analysis 2.1) or when defined as at
least a 50% improvement (RR 0.89, 95% CI 0.47 to 1.67) (see
Analysis 2.2).
A significant difference in pain (MD45.17, 95%CI 8.73 to 81.61)
(see Analysis 3.1) was seen in the small sub-sample of 11 ELP par-
ticipants in the Yoke 2006 study in favour of ciclosporin solution
when compared to 0.1% triamcinolone acetonide (potent topical
steroid).
In the Radfar 2008 study comparing 0.1% tacrolimus against
0.05% clobetasol propionate, no significant reduction in pain was
seen between the 2 groups (MD -0.64, 95% CI -1.91 to 0.63) (see
Analysis 4.1).
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In the Choonhakarn 2008 study, aloe vera gel was 6 times more
likely to result in at least 50% improvement in pain symptoms
when compared to placebo (RR 6.16, 95% CI 2.35 to 16.13) (see
Analysis 5.1).
Additionally, in the Conrotto 2006 study comparing 1.5% ci-
closporin against 0.025%clobetasol propionate, no significant dif-
ference was seen for at least a 50% improvement in pain (RR 0.47,
95% CI 0.17 to 1.32) (see Analysis 6.1).
In the Hegarty 2002 cross-over trial (n = 22) comparing flutica-
sone propionate spray against betamethasone sodium phosphate
mouthwash, no statistical testing of the comparison for the pain
score (VAS 0 to 100 score) was reported within the paper; there-
fore, it is not clear whether the difference is statistically significant
or not (fluticasone [mean score 19.8] versus betamethasone [mean
score 26]).
Volz 2008 only presented data for baseline and P values for changes
in scores for each of the treatment groups without P values com-
paring the scores between the treatment groups.
We were unable to extract data on participant-reported symptoms
for Eisen 1990 because there was no breakdown of data for the
ELP subgroup.
(b) Physician Global Assessment (e.g. five-point)
No significant differences were seen for improvement in clini-
cal response (defined using the Thongprasom score) between the
0.025% clobetasol-17-propionate and 0.025% conventional for-
mulation groups in the Campisi 2004 study (MD 0.00, 95% CI
-0.61 to 0.61) (see Analysis 2.3), between 0.025% clobetasol pro-
pionate and 0.05% clobetasol propionate groups in the Carbone
2009 study (MD 0.47, 95% CI -0.26 to 1.20) (see Analysis 2.3),
or between the 0.1% triamcinolone acetonide versus ciclosporin
solution in the Yoke 2006 study (MD 0.61, 95%CI -0.79 to 2.01)
(see Analysis 3.2).
No significant differences were seen for improvements in clini-
cal response (defined using the Thongprasom score) between the
0.025% and 0.05% clobetasol propionate groups in the Carbone
2009 study (RR 1.14, 95% CI 0.56 to 2.35) (see Analysis 2.4),
or between the aloe vera and placebo groups in the Choonhakarn
2008 study (RR 2.64, 95% CI 0.11 to 61.54) (see Analysis 5.2).
However, in the Conrotto 2006 study a significant difference was
seen in favour of the 1.5% ciclosporin gel compared to 0.025%
clobetasol propionate gel (RR 3.16, 95% CI 1.00 to 9.93) (see
Analysis 6.2).
In the Eisen 1990 study, a significant difference was seen for an
improvement in the severity of the disease in favour of the ci-
closporin group when compared to the vehicle (MD -1.40, 95%
CI -1.86 to -0.94) (see Analysis 6.3).
In the Lin 2005 study, no significant difference was seen for an
improvement in clinical response (defined as remarkably effective)
in favour of TGT when compared to THT (RR 0.55, 95% CI
0.25 to 1.20) for grade I (erosive and ulcerative) lesions or for
grade II (erosive) lesions (RR 0.73, 95% CI 0.42 to 1.28) (see
Analysis 7.1).
In the Malhotra 2008 study, a significant improvement in clinical
severity was seen at the end of the trial (at 24 weeks) in favour
of 0.1% topical triamcinolone acetonide paste when compared to
betamethasone oral mini-pulse therapy (MD 1.78, 95% CI 0.17
to 3.39) (see Analysis 9.1). However, no significant differences
between the treatment groups were detected at earlier outcome
timings.
In the Passeron 2007 study, no significant difference was seen for
an improvement in clinical response (defined as surface of erosive
lesions) between the 1% pimecrolimus and placebo groups (MD
-0.50, 95% CI -1.39 to 0.39) (see Analysis 1.3).
In the Volz 2008 study, 1% pimecrolimus cream was 7 times more
likely to result in a strong improvement as rated by the Physician
Global Assessment when compared to vehicle cream (RR 7.00,
95% CI 1.04 to 46.95) (see Analysis 1.4).
In the Voute 1993 study, no significant difference in improvement
in clinical response (defined as complete response) was seen be-
tween the fluocinonide and placebo groups (RR 4.67, 95% CI
0.24 to 88.96) (see Analysis 8.1).
In the Swift 2005 study, no significant difference was seen for
an improvement in clinical response (defined as a weighted sum
of ulceration, erythema, and reticulation between the 1% pime-
crolimus and placebo groups) (MD -56.57 mm², 95%CI -134.02
to 20.88 mm²) (see Analysis 1.2).
(c) Participant global self-assessment
One study (Passeron 2007) assessed the participants global self-as-
sessment using a 5-point scale, and found 5 out of 6 participants in
the 1% pimecrolimus group rated their improvement as moderate
or important, with the other participant rating no improvement.
This was compared to 1 out of 6 participants in the placebo group
who rated their improvement as moderate or important. Of the
other 5 participants in this group, 2 rated their improvement as
fair, 1 had no improvement, 1 was worse, and 1 gave no score (P
= 0.316, Fishers Exact test).
Secondary outcomes
Again, there was no consensus regarding secondary outcome mea-
sures (Table 2).
(a) Complete clinical response defined as the percentage of
participants with complete resolution of clinical signs or
symptoms
In the Volz 2008 study, the difference in complete clearance be-
tween participants randomised to 1% pimecrolimus cream or ve-
hicle creamwas not statistically significant (RR 3.50, 95%CI 0.95
to 12.90) (see Analysis 1.5).
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(b) Partial response defined as the percentage of
participants with at least 50% improvement
In the Carbone 2009 study, no significant difference was seen for
an improvement in clinical response (defined as partial or complete
response) between the 0.025% and 0.05% doses of clobetasol
propionate groups (RR 1.18, 95% CI 0.82 to 1.70).
In theConrotto 2006 study, a significant difference was seen for an
improvement in clinical response (defined as partial or complete
response) in favour of 1.5% ciclosporin gel when compared to
0.025%clobetasol propionate gel (RR1.46, 95%CI1.04 to 2.04).
In the Choonhakarn 2008 study, a significant difference in im-
provement in clinical response (defined as 50% or more improve-
ment) was seen in favour of the aloe vera groups when compared
to placebo (22/24 versus 1/21, respectively) (RR 19.25, 95% CI
2.83 to 130.85).
In the Lin 2005 study, a significant difference was seen in im-
provement in clinical response (defined as remarkably effective or
effective) in favour of TGTwhen compared to THT (THT versus
TGT - RR 0.18, 95% CI 0.04 to 0.82) for grade I (erosive and
ulcerative) lesions; however, no significant difference was seen for
grade II (erosive) lesions (THT versus TGT - RR 0.29, 95% CI
0.07 to 1.27).
In the Voute 1993 study, no significant difference in improvement
in clinical response (defined as more than 33% improvement) was
seen between the fluocinonide and placebo groups (RR 3.00, 95%
CI 0.62 to 14.62).
(c) Reduction in severity of flares
No studies reported this outcome.
(d) Reduction in number of flares
No studies reported this outcome.
(e) Relapse rate when medications are stopped or reduced
In Passeron 2007’s study (n = 12) comparing 1% pimecrolimus
cream to placebo for 4 weeks to treat erosive oral lichen planus,
all participants who improved during treatment relapsed within 1
month of ceasing treatment.
Topical clobetasol gave less stable results than ciclosporin when
therapy ended and showed a higher incidence of side-effects (
Conrotto 2006) (n = 40).
(f) Dermatology quality of life measures
In the Hegarty 2002 cross-over trial (n = 22) comparing flutica-
sone propionate spray against betamethasone sodium phosphate
mouthwash, no statistical testing of the comparison for the Oral
Health Quality of Life index (OHQoL16) was reported within
the paper. Therefore, it is not clear whether the difference is sta-
tistically significant or not (fluticasone [mean score 0.7] versus be-
tamethasone [mean score -0.8]).
(g) Restoration of sexual activity (of most relevance to
genital sites)
None of the included studies assessed the effectiveness of treat-
ments of genital ELP; thus, this outcome was not reported.
(h) Eating a normally varied diet (most relevant to oral
involvement)
No studies reported this outcome.
(i) Side-effects reported
Several side-effects were reported, but none were serious (see
Table 3). With topical corticosteroids, the main side-effects were
oral candidiasis and dyspepsia (Campisi 2004; Conrotto 2006;
Malhotra 2008; Yoke 2006). Fluticasone propionate spray caused
nausea, swollen mouth, bad taste and smell, dry mouth, and a sore
throat (Hegarty 2002) in a small proportion of participants, but
they did not necessitate withdrawal of therapy. There were no re-
ported side-effects with topical mesalazine gel (Sardella 1998). Up
to one-third of participants receiving betamethasone oral mini-
pulse therapy reported transient oedema of the face, hands, and
feet; epigastric discomfort; and fatigue (Malhotra 2008).
Two participants receiving aloe vera gel reported transient stinging
and mild itching at lesions that disappeared after the first week
(Choonhakarn 2008). Transient burning of mucosal surfaces dur-
ing swishing of ciclosporin rinse was reported (Eisen 1990). Partic-
ipants receiving topical ciclosporin reported rashes (n = 2), parotid
(salivary gland) swelling (n = 1), dyspepsia (n = 3) (Conrotto
2006), and transient burning (Yoke 2006). Participants receiv-
ing pimecrolimus 1% cream (Passeron 2007; Swift 2005) and
tacrolimus 0.1% ointment (Radfar 2008) reported transient burn-
ing within the first 2 weeks, resulting in withdrawal of therapy in
1 participant in the latter study.
Menstrual disturbance was reported in six participants and leu-
copenia in one participant receiving tripterygiumglycosides tablets
(Lin 2005), which are known to be cytotoxic and unsuitable for
individuals of child-bearing age.
(j) Reduction in target/mean lesion size (for oral lesions)
In the Hegarty 2002 cross-over trial (n = 22) comparing flutica-
sone propionate spray against betamethasone sodium phosphate
mouthwash, no statistical testing of the comparison for the mean
surface area of lesions was reported within the paper; therefore,
it is not clear whether the difference is statistically significant or
not (fluticasone [mean score 547.2 mm²] versus betamethasone
[mean score 671.9 mm²]).
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In the Radfar 2008 study, no significant difference in lesion size
was seen between the 0.1% tacrolimus and 0.025% clobetasol
propionate groups (MD 0.00, 95% CI -1.09 to 1.10).
D I S C U S S I O N
Summary of main results
There are very few RCTs in the literature for the treatment of
erosive lichen planus (ELP) affecting mucosal sites. Most RCTs
that do exist focus only on oral disease. Topical potent steroids are
the widely accepted first-line treatment, but no overwhelming ev-
idence exists to support this. There is weak evidence that 0.025%
clobetasol propionate lipid-loaded microspheres significantly re-
duce pain compared to conventional ointment in a study of 50
participants (however, outcome data were only available from 45
of the participants recruited). Ciclosporin solution reduced pain
significantly compared to 0.1% triamcinolone acetonide in a small
subset of 11 participants. Aloe vera gel was 6 times more likely to
produce at least 50% improvement in pain compared to placebo.
There was no significant difference in clinical severity rated by
physicians or participants in any of the included studies (Carbone
2009; Conrotto 2006; Radfar 2008; Voute 1993; Yoke 2006).
This review suggests that there is only weak evidence for the ef-
fectiveness of any of the treatments for oral ELP. No evidence was
found for genital ELP; this may be because studies on genital ELP
are more difficult to conduct than oral ELP. In addition, the RCTs
were heterogenous in disease definition, outcome variables, mea-
surement scales, and assessment intervals; hence, pooling of data
was not possible for meta-analysis. Three studies based their clin-
ical diagnosis on the WHO criteria 1978 for oral precancerous le-
sions (Kramer 1978). This clearly defines their criteria for clinical
assessment. However, there is no WHO criteria for the diagnosis
of vulval ELP.
The most commonly used clinical severity tool was adopted from
the criteria first used by Thongprasom 1992, although this is not
validated and applies only to oral lesions. No validated clinical
severity tool is available for genital lesions. The most commonly
used symptom-scoring tool was a visual analogue scale (VAS) of
0 to 10 or 0 to 100 for pain, rated by participants. It has been
suggested that the VAS is non-linear and prone to bias, which lim-
its its use as a serial measure of pain (Langley 1985). One study
utilised the McGill Pain Questionaire, which measures several di-
mensions of pain and may be a better alternative to VAS (Langley
1985). Severity and duration of lesions were reported in only two
studies (Passeron 2007; Radfar 2008). This is important because
new-onset, previously untreated lesions may respond more readily
to treatment than long-standing refractory lesions, even after the
wash-out period.
Therapeutic regimens were continued over four weeks to six
months. All but one study (Lin 2005) had assessment intervals of
two to four weeks during the trial period, which made assessments
at baseline and at three months. Most of the outcome assessment
points ended too early after the completion of the therapeutic
regimen. Only 7 studies followed up participants after comple-
tion of the treatment regimen for 1 to 17 months (Campisi 2004;
Carbone 2009; Conrotto 2006; Passeron 2007; Volz 2008; Voute
1993; Yoke 2006); hence, long-term data on relapse rate and side-
effects is unknown. This is important as ELP is a chronic, relaps-
ing, and remitting condition, and many affected individuals flare
on cessation of therapy.
Overall completeness and applicability of
evidence
Most of the studies in this reviewhad small numbers of participants
(range 12 to 139). The majority of the studies were heterogenous
in outcome variables and disease severity scoring tools. All of the
included studies recruited participants with oral disease; almost
half of the studies recruited participants with all types of OLP
and presented data for the erosive subset. Pooling of data was not
possible with any of the studies. More RCTs on a larger scale are
needed, using standardised outcome measures and well-validated
severity scoring tools in the oral and genital ELP populations.
Quality of the evidence
There were only a very small number of included RCTs, none of
which included vulval ELP. All but three included studies specif-
ically stated the method of randomisation. Only half of the in-
cluded studies stated themethodof allocation concealment. Blind-
ing of participants was not possible in four studies as different
delivery systems were used. Of the nine studies that recruited only
ELP participants, six studies performed intention-to-treat (ITT)
analyses. Of the six studies which recruited both ELP and non-
ELP participants, five performed ITT analyses.
Potential biases in the review process
Two authors (SCh andRM) reviewed the full texts separately using
a data extraction proforma. Two authors (SCh and RM) indepen-
dently confirmed eligibility, assessed quality, and extracted data.
The method of randomisation was not clarified in three studies
(Campisi 2004; Voute 1993; Yoke 2006). Where the allocation
concealment method was not specified (in eight studies), no fur-
ther clarification was sought. This may be a potential source of
bias.
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Agreements and disagreements with other
studies or reviews
ACochrane reviewupdate on ’Interventions for oral lichen planus’
has recently been published (Thongprasom 2011). The authors
concluded that there is a lack of strong evidence supporting the ef-
fectiveness of any therapy for oral lichen planus. Another system-
atic review focusing on treatments used in oral LP (Zakrzewska
2005) concluded that due to small study sizes, lack of standard-
ised outcome measures, and high likelihood of publication bias,
the results are not reliable.These conclusions are similar to our
study results in terms of lack of evidence of efficacy of any type of
treatment for erosive lichen planus, small study sizes, and lack of
standardised outcome measures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a lack of strong evidence supporting the efficacy of any
therapy for ELP affecting mucosal surfaces. Very few well-con-
ducted RCTs exist for the treatment of ELP. Most of those that do
exist come from the oral medicine literature with small numbers
of participants. Even though topical steroids are universally used
as first-line therapy for ELP, there is no overwhelming evidence
for the efficacy of any single treatment.
Implications for research
We suggest that future studies should have standardised outcome
variables that are clinically important to affected individuals, such
as the use of a modified standardised dermatology quality of life
(QOL) questionnaire (e.g. the Dermatology Quality of Life In-
dex [DLQI]), to measure the impact on daily activities of mucosal
disease. Erosive lichen planus potentially interferes with daily ac-
tivities, such as eating and sexual function; hence, QOL is an im-
portant parameter to measure. Moreover, many individuals may
not necessarily divulge such difficulties in daily life due to em-
barrassment unless asked specifically; thus, this should be assessed
routinely.
The measurement of clinical severity score and participant-rated
symptom score should be performed using agreed and/or validated
severity scoring tools, such as the scoring system validated for
oral lichen planus (Escudier 2007). Studies including both oral
and genital sites should be encouraged due to the pattern of the
disease.We suggest the development of an agreed and/or validated
combined severity scoring tool for oral and genital disease. In
addition, there is a real need for well-designed RCTs on systemic
therapy with newer biological agents for the treatment of severe
ELP refractory to first-line treatment with topical steroids.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Campisi 2004
Methods Phase IV, randomised, observer-blinded, parallel group clinical trial
Setting
Section of Oral Medicine, Department of Oral Sciences, University of Palermo, Italy
Participants Inclusion criteria of the trial
Symptomatic atrophic/erosive OLP clinically and histology, no previous treatment in
past 6 months
Total n = 50 (lipid-loaded microspheres 0.025% - n = 20, conventional formulation
ointment - n = 30)
Interventions Comparison of drug delivery system of clobetasol-17-propionate
A: Lipid-loaded microspheres 0.025%
B: Conventional formulation lipophilic ointment in hydrophilic phase 0.025%
Applied twice daily for 1 month then once daily for 1 month
Outcomes Primary outcomes of the trial
1. VAS 0 to 100
2. Clinical score 0 to 5 (Thongprasom 1992)
3. Not assessed
Secondary outcomes of the trial
1. Clinical resolution of index lesion
Outcomes not prespecified in the protocol
• Compliance (nominal variables: good, sufficient, scarce)
Assessment points Week 0, 4, and 8
Side-effects reported Oral candidiasis (1 in lipid-loaded microspheres group, 2 in conventional ointment
group)
Reported results No significant difference between the 2 groups
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation.
Allocation concealment (selection bias) Unclear risk Not specifically stated.
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Campisi 2004 (Continued)
Blinding (performance bias and detection
bias)
Participants
High risk Participants not blinded (different bases).
Blinding (performance bias and detection
bias)
Clinician
Low risk Quote: “A single blind observer...different
from the administrator...”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 5 losses, 50 randomised.
No ITT.
Selective reporting (reporting bias) Low risk All 4 outcomes reported.
Carbone 2009
Methods Randomised controlled trial to compare 2 preparations with different concentrations
Setting
Oral Medicine Section of the Department of Biological Sciences and Human Oncology,
Univerisity of Turin
Participants Inclusion criteria of the trial
Histological diagnosis of OLP on the basis of WHO criteria, presence of painful and
atrophic-erosive oral lesions at the same time as with reticular ones
Total n = 35 (arm 1 - n = 18, arm 2 - n = 17)
Interventions A: Topical clobetasol propionate 0.025% (arm 1)
B: Clobetasol propionate 0.05% (arm 2)
Applied twice daily for 2 months and antimyotic prophylaxis for both groups
Outcomes Primary outcomes of the trial
1. Symptoms (VAS 0 to 10)
Symptom response at end of treatment (week 8) compared to baseline defined as follows:
• Complete response = absence of any discomfort or symptoms
• Partial response = decrease in VAS
• Worsening = increase in VAS
• Persisting = no change in VAS
2. Clinical score 0 to 5 (Thongprasom 1992)
• Complete response = disappearance of all lesions
• Partial response = decrease score
• Worsening = increase score
• Persisting = no change in score
3. Not assessed
Outcomes not prespecified in the protocol
• Stability of the obtained results in the 8 weeks following suspension of treatment
Assessment points Week 0, 2, 4, 6, 8, and 16
Side-effects reported None reported
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Carbone 2009 (Continued)
Reported results Clinical score/response and VAS (no significant difference between the 2 groups at 2
months)
Notes Excluded skin, genital, or other extra-oral lesions
Clobetasol propionate 0.05% (Clobesol, Glaxo, Verona, Italy) is the drug that is com-
mercially available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number ta-
bles.
Allocation concealment (selection bias) Unclear risk Not specifically stated.
Blinding (performance bias and detection
bias)
Participants
Low risk During treatment neither the physician nor
the participants knew exactly which of the
2 medications they were using
Blinding (performance bias and detection
bias)
Clinician
Low risk During treatment neither the physician nor
the participants knew exactly which of the
2 medications they were using
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 35 randomised, 5 losses
due to personal reasons (3 in arm 1, 2 in
arm 2) - not included in final analysis
Selective reporting (reporting bias) Low risk Symptom response, clinical response, and
stability of results reported
Choonhakarn 2008
Methods Randomised controlled trial
Author contacted (c choonhakarn dermatologist@hotmail.com) - replied with break-
down of data for erosive subtype
Setting
Division of Dermatology, Srinagarind Hospital, Faculty of Medicine, Khon Kaen Uni-
versity
Participants Inclusion criteria of the trial
Clinical and histological diagnosis of oral LP over 18 years
Total n = 54 (only 45 had erosive/atrophic LP, of which n = 24 in aloe vera group, n =
21 in placebo group)
Interventions A: Aloe vera (AV) gel
B: Placebo gel
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Choonhakarn 2008 (Continued)
Applied twice daily for 8 weeks
Outcomes Primary outcomes of the trial
1. VAS 0 to 10
Symptom response at end of treatment (week 8) defined as follows:
• Complete response = VAS of 0
• Good response = VAS decrease by 50% or more from baseline
• Poor response = VAS decrease by < 50% from baseline
• No response = VAS unchanged
2. Clinical score 0 to 5 (Thongprasom 1992)
Clinical response at end of treatment (week 8) defined as follows:
• Complete response = score 0 to 1
• Good response = score decrease by 50% or more from baseline
• Poor response = score decrease by < 50% from baseline
• No response = unchanged
3. Not assessed
Assessment points Week 0, 2, 4, 6, and 8
Side-effects reported No serious side-effects. 2 receiving aloe vera gel reported stinging and mild itching at
lesions within the first week, but symptoms spontaneously disappeared with continued
use
Reported results No reported results for erosive subgroup of participants as trial included non-erosive
OLP
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple random number tables.
Allocation concealment (selection bias) Low risk AV gel and placebo gel were prepared by
the Faculty of Pharmaceutical Sciences,
Khon Kaen province. The study medica-
tions were packed in identical containers,
and the code was kept at the Faculty of
Pharmaceutical Sciences until completion
of the study
Blinding (performance bias and detection
bias)
Participants
Low risk The medication used was unknown to par-
ticipants or physicians
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Choonhakarn 2008 (Continued)
Blinding (performance bias and detection
bias)
Clinician
Low risk The medication used was unknown to par-
ticipants or physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Low risk Symptom and clinical response reported.
Conrotto 2006
Methods Randomised controlled, double-blind study
Setting
Oral Medicine Section of the Department of Biological Sciences and Human Oncology,
University of Turin
Participants Inclusion criteria of the trial
Oral lichen planus on the basis of WHO criteria, atrophic/erosive type (duration not
stated)
Total n = 40 (clobetasol - n = 20, ciclosporin - n = 20)
Interventions A: Clobetasol topical 0.025% gel
B: Ciclosporin topical 1.5% gel
Applied twice daily for 2 months (same scoop) in the same base (hydroxyethyl cellulose
adhesive gel)
Outcomes Primary outcomes of the trial
1. VAS 0 to 10
2. Clinical score 0 to 5 (Thongprasom 1992)
Symptom and clinical response at end point compared with baseline:
• Complete response = disappeared
• Partial = decrease score
• No change = same score
• Worse = increase score
3. Not assessed
Assessment points Fortnightly for 4 months
Side-effects reported Ciclosporin: Skin rashes (2), parotid swelling (1), and dyspepsia (3)
Clobetasol: Dyspepsia (1)
Reported results Topical Dermovate better than topical ciclosporin in inducing clinical improvement, but
both drugs had comparable effects on symptoms
Notes -
Risk of bias
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Conrotto 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number ta-
bles.
Allocation concealment (selection bias) Low risk Medication was distributed in identical
containers, packed by someone who was
unaware of the study
Blinding (performance bias and detection
bias)
Participants
Low risk During treatment neither the physician nor
the participants knew which of the 2 med-
ications they were using
Blinding (performance bias and detection
bias)
Clinician
Low risk During treatment neither the physician nor
the participants knew which of the 2 med-
ications they were using
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 40 randomised, 1 lost as
they did not attend (no reason given). They
were not included in final analysis
Selective reporting (reporting bias) Low risk Symptom and clinical response reported.
Eisen 1990
Methods Randomised controlled, double-blind study
Setting
Department of Dermatology, University of Michigan Medical Centre
Participants Inclusion criteria of the trial
Clinical and biopsy-proven OLP
Total n = 16 (only 8 had ELP, of which n = 5 in ciclosporin rinse group, n = 3 in vehicle)
Interventions A: Topical ciclosporin rinse
B: Placebo (vehicle only)
Applied thrice daily for 8 weeks - 100 mg/ml, swish 5 ml solution (500 mg for active
group) in mouth, expectorate after 5 minutes
Outcomes Primary outcomes of the trial
1. Participant-rated symptom scores on a scale of 0 to 3 (0=nopain, 3 = severe discomfort)
2. Clinical score 0 to 3 for each lesion (0 = no disease, 3 = severe disease) for erosion,
erythema, and reticulation
Mean scores were averaged for each participant
Global scores reported at end of treatment compared with baseline as follows:
• -1 = worse
• 0 = no change to minimal improvement (< 20%)
• 1 = moderated improvement (20% to 40%)
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Eisen 1990 (Continued)
• 2 = marked improvement (50% to 80%)
• 3 = almost complete or complete improvement (81% to 100%)
3. Not assessed
Assessment points Week 0, 2, 4, 6, and 8
Side-effects reported No adverse side-effects. Transient burning sensation of mucosal surfaces during swishing
of medication reported in all participants
Reported results No reported results for erosive subgroup of participants as trial included non-erosive
OLP
Notes Open phase for 8 weeks: placebo group subsequently received ciclosporin rinse for 8
weeks at end of double-blind phase
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Unclear risk Not specifically stated.
Blinding (performance bias and detection
bias)
Participants
Low risk During the initial 8 weeks neither the
physician responsible for evaluating the
participants nor the participants knew
the identity of the medications dispensed,
which were identical in appearance and
taste
Blinding (performance bias and detection
bias)
Clinician
Low risk During the initial 8 weeks neither the
physician responsible for evaluating the
participants nor the participants knew
the identity of the medications dispensed,
which were identical in appearance and
taste
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Low risk Mean symptomand clinical scores reported
at baseline and end of therapy (week 8)
Global scores - 1 to 3 reported individ-
ually for erythema, erosions, reticulation,
and symptoms at week 8
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Hegarty 2002
Methods Randomised cross-over study
Author contacted on 1 February 2010 to confirm cross-over was performed and results
reported
Setting
Eastman Dental Institute for Oral Health Care Sciences, University of London
Participants Inclusion criteria of the trial
Histological diagnosis and symptomatic erosive/ulcerative LP
Total n = 44
Interventions Sequence 1:
A: Fluticasone propionate (FP) spray 50 mcg 2 puffs - QDS (n = 22)
B: Betamethasone sodium phosphate (BSP) mouthwash 500 mcg - QDS (n = 22)
Applied for 6 weeks
Sequence 2:
Followed by 2-week wash-out then cross-over
Outcomes Primary outcomes of the trial
1. VAS (0 to 100)
2. Clinical score 0 to 5 (Thongprasom 1992)
3. Not assessed
Secondary outcomes of the trial
1. Total surface area of all lesions mm² (reported at week 0 and 6)
2. Oral Health Impact Profile (OHIP)
3. Oral Health QoL questionnaires (OHQOL)
4. McGill pain score
Assessment points Week 0, 3, 11, and 14
Side-effects reported Fluticasone propionate spray: nausea (4), swollen mouth (1), bad taste and smell (6),
difficulty in spray application (7), dry mouth (2), sore throat (1), red and painful tongue
(1), and pseudomembranous candidiasis (1)
Betamethasone mouthwash: none reported
Reported results Change at week 6 from baseline significant for both groups. No significant difference
between the 2 groups in decreasing VAS or QOL. FP significantly better than BSP in
decreasing surface area of lesions
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of randomised numbers.
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Hegarty 2002 (Continued)
Allocation concealment (selection bias) Unclear risk A dedicated nurse, who also administered
the participant assessment questionnaires,
undertook the randomisation and assign-
ment. The sequence was concealed until
the effect of both interventions was anal-
ysed
Blinding (performance bias and detection
bias)
Participants
High risk Different delivery systems.
Blinding (performance bias and detection
bias)
Clinician
Low risk The examining physician was blinded to
the medication sequence
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) High risk All outcomes reported except Primary 2
(Thongprasom results)
Lin 2005
Methods Randomised controlled trial
Setting
Department of Periodontal Disease, Hospital of Stomatology, Shandong University,
Jinan
Participants Inclusion criteria of the trial
“Peridontal diseases” diagnostic standard on histology erosive oral lichen planus
Total n = 94
Grade I: erosive and ulcerative lesions (TGT: n = 21, THT: n = 21)
Grade II: erosive lesions only (TGT: n = 26, THT n = 26)
Interventions A: Radix tripterygium hypoglaucum tablets (THT) - 5 tablets TDS
B: Tripterygium glycosides tablets (TGT) - 1.0 to 1.5 mg/kg TDS
Applied for 3 months
Taper dose after 2 to 4 weeks
Outcomes Primary outcomes of the trial
1. Not assessed
2. Reduction in clinical severity, defined as remarkably effective, effective, or ineffective:
• Remarkably effective = erosive lesions cured completely, showing the same colour
as that of the tissues around, with or without whitish mesh
• Effective = erosive lesions cured with “partially remained flush of membrane and
colour of white mesh turning to light”
• Ineffective = erosions and congestions remaining
3. Not assessed
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Lin 2005 (Continued)
Assessment points Baseline and at end of 3 months
Side-effects reported TGT: Menstrual disturbance (6) and leucopenia (1)
Reported results TGT superior to THT in reducing clinical severity (P = 0.043), but more side-effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Number table.
Allocation concealment (selection bias) Unclear risk Not specifically stated.
Blinding (performance bias and detection
bias)
Participants
Unclear risk Not specifically stated.
Blinding (performance bias and detection
bias)
Clinician
Unclear risk Not specifically stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Low risk All outcomes reported.
Malhotra 2008
Methods Randomised comparative study
Author contacted (binodkhaitan@hotmail.com) - replied with breakdown
Setting
Department of Dermatology and Venereology, All India Institute of Medical Sciences
Participants Inclusion criteria of the trial
Clinical OLP. Total n randomised = 49 (group A [mini-pulse therapy] - n = 25, group B
[topical triamcinolone acetonide] - n = 24)
No histology
Erosive subgroup: total n = 22 (group A - n = 15, group B - n = 7)
11 out of 15 in group A and 5 out of 7 in group B who had erosions completed the
follow-up period
Interventions A: Betamethasone oral mini-pulse therapy - 5 mg 2 consecutive days/week
B: Topical triamcinolone acetonide (0.1%) paste - TDS
Applied for 6 months - above doses for 3 months, then taper dose
31Interventions for erosive lichen planus affecting mucosal sites (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Malhotra 2008 (Continued)
Outcomes Primary outcomes of the trial
1. Not assessed
2. Mean severity scores (Score of 0 to 12 on a clinical scoring system where the extent
of involvement of the buccal mucosa, tongue, lips, gingiva, and palate are scored and
added up to a maximum of 12 points)
• Grade 0 = 0 points
• Grade I = 1 to 3 points
• Grade II = 4 to 6 points
• Grade III = 7 to 12 points
Reported as mean severity score at baseline and subsequent follow-ups for both groups
3. Not assessed
Outcomes not prespecified in the protocol
• Subjective response was considered only if the participant achieved asymptomatic
state. Changes in symptoms evaluated on a scale of 0% to 100%, with 10% as a unit.
(Emailed author again for breakdown 19 February 2010 - no response)
Assessment points Week 0, 2, 4, 8, 16, 20, and 24
Side-effects reported Betamethasone: oedema over face (transient) (7), oedema over hands and feet (4), epigas-
tric discomfort (7), weakness/fatigue (5), loose stools (1), headache (1), diabetes mellitus
(1), weight gain (1), and dry mouth (1)
Triamcinolone: epigastric discomfort (1) and candidiasis (5)
Reported results No reported results for erosive subgroup of participants as trial included non-erosive
OLP. Breakdown of mean severity scores for erosive subgroup obtained from authors via
email
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk Sealed envelopemethod (unclear if sequen-
tially numbered and opaque)
Blinding (performance bias and detection
bias)
Participants
High risk Different delivery systems. Quote: “Limi-
tations: The study was not blinded...”
Blinding (performance bias and detection
bias)
Clinician
Unclear risk Not specifically stated.
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Malhotra 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 losses to follow-up (2 from group A and
1 from group B) were not included in final
analysis. No ITT
Selective reporting (reporting bias) Low risk All outcomes reported.
Passeron 2007
Methods Randomised, double-blind, prospective trial
Setting
Department of Dermatology, University Hospital of Nice
Participants Inclusion criteria of the trial
Histological diagnosis of erosive oral lichen planus, must have had at least 1 other
treatment, > 25% mucosal involvement grade 4 (duration not stated)
Total n = 12 (1% pimecrolimus cream - n = 6, vehicle - n = 6)
Interventions A: 1% pimecrolimus cream
B: Vehicle (placebo)
Applied twice daily for 4 weeks
Outcomes Primary outcomes of the trial
1. Spontaneous and meal-triggered pain (scored 0 to 4 on a VAS)
2. Surface area involved (% involvement on ordinal scale 1 to 4)
• 1 = < 5% involvement
• 2 = 5% to 15% involvement
• 3 = 16% to 25% involvement
• 4 = > 25% involvement
The sum of all 3 scores for spontaneous pain, meal-triggered pain, and surface area
involved gave a maximum score of 12
3. Subjective participant assessment at end of study (questionnaire - score as follows:
worse, no effect, or mild; moderate; or important improvement)
Secondary outcomes of the trial
1. Pimcrolimus level in blood, blood pressure, blood laboratory investigations, and ad-
verse events
Assessment points Week 0, 4, and 8
Side-effects reported Pimecrolimus well-tolerated, transient burning (2) during first 2 weeks
Reported results 1% Pimecrolimus cream effective compared with placebo. Well-tolerated
All participants in the pimecrolimus group whose condition improved had a relapse
within the month following the end of treatment
Notes Hard to blind a trial when participants are aware of side-effects of burning with active
agent
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Passeron 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Draw lots, with equilibration every 4 sub-
jects.
Allocation concealment (selection bias) Unclear risk Not specifically stated in paper.
Blinding (performance bias and detection
bias)
Participants
Unclear risk Stated as “double-blind” in title, abstract,
and methods.
Blinding (performance bias and detection
bias)
Clinician
Unclear risk Stated as “double-blind” in title, abstract,
and methods.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included in analysis. ITT.
Selective reporting (reporting bias) Low risk All outcomes reported.
Radfar 2008
Methods Randomised, comparative, double-blind study
Setting
Oral Medicine Clinic at the School of Dental Medicine, State University of New York
at Buffalo
Participants Inclusion criteria of the trial
Histological diagnosis of OLP and clinically symptomatic oral lesions. All participants
had erosive/ulcerative LP. Oral lesions 10 mm or more
Total n = 29 (tacrolimus - n = 15, clobetasol - n = 14)
Interventions A: Topical tacrolimus 0.1% ointment
B: Clobetasol propionate 0.05% ointment
Applied for 6 weeks (QDS 2 weeks, TDS 2 weeks, BD 1 week, OD 1 week) and nystatin
oral rinse once daily in both groups
Outcomes Primary outcomes of the trial
1. Symptomatology score VAS 0 to 10
• Complete response = VAS 0 (absence of any discomfort)
• Partial response = decrease in VAS
• Worsening = increase in VAS
• Persistence = no change in VAS
2. Not assessed
3. Not assessed
Secondary outcomes of the trial
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Radfar 2008 (Continued)
1. Measurement of target lesion size (longest dimension, picture taken with ruler in
place)
Complete response (disappearance of lesions) = 1. Scores were either 0 or 1
2. Telephone interview 9 months after completion of treatment about their lesion-free
period after completion of study
Assessment points Week 0, 2, and 6
Side-effects reported Burning sensation with topical tacrolimus
Reported results Tacrolimus as useful as clobetasol in the treatment of OLP
No significant difference between both groups
Notes Clinical severity was assessed by measuring mean lesion size rather, than a Physician
Global Asessment (using an ordinal scale)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number ta-
bles.
Allocation concealment (selection bias) Low risk Ointments were prepackaged by university
pharmacists in identical containers
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “During treatment, neither the
practitioners nor the participants were
aware of the medications they were using.”
Blinding (performance bias and detection
bias)
Clinician
Low risk Quote: “During treatment, neither the
practitioners nor the participants were
aware of the medications they were using.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Data from 29 patients were ana-
lyzed...”
Comment: losses to follow-up: 29 ran-
domised. 2 losses (burning sensation, no
reason)
Selective reporting (reporting bias) Low risk Primary and secondary outcomes reported.
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Sardella 1998
Methods Randomised controlled trial
Setting
Department of Oral Pathology and Medicine, University of Milan
Participants Inclusion criteria of the trial
WHO criteria symptomatic and previous untreated OLP, histological confirmation
(group A - n = 14, group B - n = 11)
Erosive/atrophic subtype: group A - n = 6 (all female), group B - n = 6 (3 male, 3 female)
Interventions A: Clobetasol propionate ointment 0.05%
B: Mesalazine gel 5% in adhesive base (Topasa gel)
Applied twice daily for 4 weeks on dried lesions
Outcomes Primary outcomes of the trial
1. VAS 0 to 10
At 4 weeks:
• Complete response = no symptoms
• Partial response = reduction in VAS
• No response = no change in VAS
2. Not assessed
3. Not assessed
Assessment points Week 0 and 4
Side-effects reported No side-effects
Reported results No reported results for erosive subgroup of participants as trial included non-erosive
OLP. Breakdown of individual VAS for each of the 25 participants at baseline and end
of treatment were reported in a table. Hence, data on the erosive subgroup was available
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Unclear risk Not specifically stated.
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...even though the patients did not
know if the tube they received from the in-
vestigator contained steroid or mesalazine.
”
Blinding (performance bias and detection
bias)
Clinician
Low risk Only VAS assessed, which is participant-
reported.
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Sardella 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Low risk All outcomes reported.
Swift 2005
Methods Randomised controlled trial
Setting
Stomatology Centre of the Baylor College of Dentistry, Dallas, Texas
Participants Inclusion criteria of the trial
Erosive oral lichen planus clinical and histology
Total n = 20 (n = 10 in each arm)
Interventions A: 1% pimecrolimus cream
B: Placebo cream BD
Applied for 4 weeks (similar 15 g tubes with a 1 ml measuring device)
Outcomes Primary outcomes of the trial
1. VAS 0 to 100
2. Clinical severity (area of ulceration + area of erythema + area of reticulation in mm²
= weighted sum)
3. Not assessed
Outcomes not prespecified in the protocol
• Laboratory studies (complete blood count, complete metabolic panel)
Assessment points Week 0, 2, and 4
Side-effects reported Pimecrolimus: slight burning tip of tongue after applying 1% pimecrolimus on gingiva
lesions, but resolved within minutes
Reported results Significant reduction in VAS (P = 0.022) in treatment group, but not lesion size
Notes Hard to blind a trial when participants are aware of the side-effects of burning with active
agent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated table of random
numbers (clarified with authors via email
trees@bcd.tamhsc.edu)
Allocation concealment (selection bias) Low risk Allocation concealment achieved by using a
placebo cream that was prepared by a phar-
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Swift 2005 (Continued)
macist and dispensed in a 15 gram tube
similar to the tube containing the pime-
crolimus. The tubes were unlabeled. Par-
ticipants in both groups received the same
1 ml measuring device and instructions to
use ¼ to½ of the 1ml scoop of medication
per application
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “Both the participants and the ex-
aminer were masked to the type of medica-
tion dispensed.”
Blinding (performance bias and detection
bias)
Clinician
Low risk Quote: “Both the participants and the ex-
aminer were masked to the type of medica-
tion dispensed.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “When the two participants
dropped out relatively early in the project
patients whomet the study criteria received
blood tests as required. The first candidate
who met all inclusion criteria was assigned
the number of the first individual who was
dropped. The same approach was taken for
the second candidate who was assigned the
number and appropriate arm of the sec-
ond patient who was dropped. Both par-
ticipants were managed identically to other
study participants and the principal inves-
tigator was blinded at all times.”
Losses to follow-up: 2 losses early on, but
replaced by other participants who were
given the original group assignment (clar-
ified with authors via email trees@bcd.
tamhsc.edu)
Selective reporting (reporting bias) Low risk All outcomes reported.
Volz 2008
Methods Randomised controlled trial
Setting
Department of Dermatology, University Hospital of Tubingen, Germany
Participants Inclusion criteria of the trial
Clinical and histological diagnosis of erosive oral LP
Total n = 20 (15 women, 5 men, n = 10 in each group)
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Volz 2008 (Continued)
Interventions A: 1% pimecrolimus cream
B: Placebo
Outcomes Primary outcomes of the trial
1. Spontaneous and food-triggered pain (VAS 0 to 10)
2a. Erosive surface area on an ordinal scale of 1 to 4 (< 5% involvement = 1, 5% to 15%
= 2, > 15% to 25% = 3, > 25% = 4)
2b. Investigator Global Assessment
IGA on a 5-point scale was determined at day 30 by qualifying the overall status of the oral
mucosa in comparison with baseline (worsening, no improvement, slight improvement,
medium improvement, and strong improvement)
Reported data as composite scores of VAS and erosive surface areas. This composite score
was the primary efficacy variable of the study. The author was contacted on 7 September
2009 and 4 October 2009 for breakdown of scores for VAS, but no response received
(tilo.biedermann@med.uni-tuebingen.de)
3. Not assessed
Assessment points Day 0, 30, and 60
Side-effects reported Pimecrolimus: burning sensation (4) and mucosal paraesthesia (1)
Placebo: burning sensation (1) and mucosal paraesthesia (1)
Reported results Significant reduction in clinical severity (P = 0.032) in treatment group as detected by
Investigator’s Global Assessment
Notes Hard to blind a trial when participants are aware of side-effects of burning with active
agent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Validated system that automated the ran-
dom assignment of treatment groups to
randomisation numbers
Allocation concealment (selection bias) Low risk Quote: “Study medication was prepared
and packaged by Novartis Pharma in iden-
tical tubes differing only in the randomisa-
tion numbers. Until unblinding, randomi-
sation data were kept strictly confidential.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “All personnel directly involved in
the conduct of the study remained blinded
to the treatment assignment until all pa-
tients had completed the study and all data
had been retrieved for finalised analysis.”
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Volz 2008 (Continued)
Blinding (performance bias and detection
bias)
Clinician
Low risk Quote: “All personnel directly involved in
the conduct of the study remained blinded
to the treatment assignment until all pa-
tients had completed the study and all data
had been retrieved for finalised analysis.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Primary analyses were performed
on the ITT population using the last obser-
vation carried forward method for missing
data.”
Selective reporting (reporting bias) Low risk All outcomes reported.
Voute 1993
Methods Randomised, double-blind, placebo-controlled clinical study
Setting
Department of Oral and Maxillofacial SUrgery and Oral Pathology, Free University
Hospital, Amsterdam
Participants Inclusion criteria of the trial
History, clinical diagnosis, histology, immunofluorescence consistent with OLP
Total n = 40
Erosive type - 2 men, 10 women. Active group = erosive 5, combination 9 = 14 total;
placebo group = erosive 7, combination 6 = 13 total
Interventions A: Fluicinomide ointment
B: Placebo (adhesive ointment base: 40% hypromellose in white soft paraffin)
Applied to dried lesions at least 6 times per day for 9 weeks
Outcomes Primary outcomes of the trial
1. VAS (scale not stated)
No breakdown of VAS for erosive subtype
2. Clinical severity (objective score) measured by comparing clinical photographs. Break-
down of erosive subtype results available
Symptom and clinical response reported at week 9. These were subdivided into 5 groups:
• 0% = no response
• < 33% = partial
• < 66% = good
• 100% = complete remission
• Increase signs
3. Not assessed
Assessment points Week 0, 3, and 9. Follow-up for 3 to 17 months after end of treatment
Side-effects reported No side-effects during study and follow-up period
Reported results Results for erosive subgroup not reported as trial included non-erosive OLP
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Voute 1993 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as randomised.
Allocation concealment (selection bias) Low risk Both the active medication and placebo
ointment were extemporaneously mixed in
the Department of Pharmacy of the Free
University Hospital, Amsterdam
Blinding (performance bias and detection
bias)
Participants
Unclear risk Stated as double-blind. Base is non-tasting.
Blinding (performance bias and detection
bias)
Clinician
Unclear risk Stated as double-blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Low risk Symptom and clinical responses reported.
Yoke 2006
Methods Randomised controlled trial
Author contacted (pcy@ndc.com.sg) - replied with breakdown of erosive subtype
Setting
Multicentre (hospital) (Singapore, India, South Korea, Thailand)
Participants Inclusion criteria of the trial
Clinical signs and symptoms, histologically confirmed OLP. N randomised = 139
Erosive subtype: total n = 15 (group A (triamcinolone acetonide) - n = 4 (outcome data
for 2 out of 4), group B (ciclosporin solution) - n = 11 (outcome data for 9 out of 11)
Interventions A: Triamcinolone acetonide in orabase TDS
B: Ciclosporin solution TDS
Appplied for 8 weeks
Outcomes Primary outcomes of the trial
1. VAS 0 to 100 for pain, VAS 0 to 100 for burning sensation
2. Clinical score 0 to 5 (most severe and extensive marker lesion) (Thongprasom 1992)
Clinical response defined as a reduction in clinical score from baseline of at least 1 unit
at 4 weeks after randomisation
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Yoke 2006 (Continued)
3. Not assessed
Secondary outcomes of the trial
1. and 2. Marker lesion size measured by a transparent grid calibrated to 2 mm squares
Assessment points Week 0, 2, 4, 6, and 8
Side-effects reported No significant adverse events. Transient burning sensation upon initial application with
both treatments
Reported results No reported results for erosive subgroup of participants as trial included non-erosive
OLP
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as “randomly assigned”, but no spe-
cific details on randomisation stated
Allocation concealment (selection bias) Low risk Central randomisation office of Clinical
Trials and Epidemiology Research Unit via
telephone (Singapore and South Korea)/
sealed envelope (India and Thailand) - not
stated if opaque
Blinding (performance bias and detection
bias)
Participants
High risk Different delivery systems.
Blinding (performance bias and detection
bias)
Clinician
Unclear risk Not specifically stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 losses to follow-up and 11 discontinued
drug, all 139 randomised participants in-
cluded in final analysis
(Breakdown of data for erosive subgroup:
incomplete outcome data for 4 out of 15
erosive subgroup participants.)
Selective reporting (reporting bias) Low risk All outcomes reported (stated under “out-
comes” that clinical response will be re-
ported, but not clinical score)
n = number
OD = once daily
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BD = twice daily
TDS = three times per day
QDS = four times per day
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bouloc 2000 Not ELP. Vignette. Compared a new vitamin D3 analogue (KH1060) with the vehicle in the treatment of
cutaneous lichen planus. One of the exclusion criteria was exclusive presence of actinic, atrophic, or bullous
variations of LP. Results table/graph not reported. Supported by Leo Pharmaceuticals Products
Buajeeb 1997 Not a RCT. Stated “randomly assigned” in abstract, but under study design stated “patients were alternately
given A or B as they presented to the clinic for treatment.”
Buajeeb 2000 Not a RCT.
Carbone 2003 Not a RCT.
Chainani-Wu 2007 The reason for exclusion is that this phase II RCT evaluated the efficacy and safety of curcuminoids as an
adjunct to short-course corticosteroids
Compared curcuminoids (standardised extract of tumeric rhizomes cultivated in India) 2000 mg/day versus
(vs) placebo for 7 weeks + oral prednisolone 60 mg for the first week in both arms
Trial ended early for futility. The first interim analysis (using data from the first 33 subjects) did not show a
significant difference between the 2 groups. Conditional power calculations suggested a less than 2% chance
that the curcuminoids group would have a significantly better outcome compared with placebo if the trial
were continued to completion. Target number was 100 participants
Chang 2008 Case series, not a RCT. 5 out of 7 had vulval ELP.
Corrocher 2008 Oral lichen planus, not erosive.
Gaeta 1994 Not a RCT. No data for placebo arm. Outcome measures not properly defined
Gorouhi 2007 Author contacted (firozali@sina.tums.ac.ir) 4 October 2009 and 14 December 2009 - no response. Only 27/
40 had ELP. No breakdown of results for ELP subgroup
Goulet 2001 Oral LP, not erosive. Pilot RCT. No sufficient data. Abstract
Hersle 1982 Oral lichen planus. Split erosive/non-erosive data combined in report, cannot extrapolate
Kellett 1990 Cutaneous, not erosive, LP.
Laeijendecker 2006 Author contacted (R.Laeijendecker@asz.nl) 14 December 2009 - no reply. OLP. 29/40 had erosive subtype.
Breakdown of results was not available; hence, the study was excluded
Lehman 2009 Review paper.
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Lener 2001 Case report (no abstract in search).
Lo Muzio 2001 Not all ELP. Recruited 54 participants with a history of vesiculo-ulcero-erosive oral lesions, of which 30 had
recurrent oral aphthous ulcers. Only 24 had oral ELP. 3 groups compared clobetasol 0.05% vs clobetasol
ointment 0.05% bioadhesive denture paste vs clobetasol 0.05% in orabase. 8 participants out of 18 with oral
lichen planus per group (remaining 10 had aphthous ulceration). Comparing 3 different groups of 18 and
comparing different vehicles. No placebo. Assuming product works. States trial is double-blind, but this is not
possible with the different vehicles used
Lozada-Nur 1994 Participants have vesiculobullous disease - LP. Benign mucous membrane pemphigoid, pemphigus vulgaris,
erythema multiforme
Lozada-Nur 2006 Open trial. Not a RCT.
Ma 2004 Not a RCT. Abstract states “random”, but text states “patients were alternately allocated into two groups”.
(Mandarin - translated.)
Mansourian 2008 Asymptomatic participants with OLP only were included in study
Mousavi 2009 Investigated the use of ignatia, a homeopathic remedy for hysteria
Participants were required to have the “mind and general symptom of Ignatia”.
Quote: “General symptoms of Ignatia include: a marked hyperesthesia of all the senses, and a tendency to
clonic spasms. Mentally, the emotional element is uppermost and co-ordination of function interfered with.
..It is especially adapted to the nervous temperament - women of sensitive, easily excited nature, dark, mild
disposition, quick to perceive, rapid in execution. Rapid change of mental and physical conditions is opposite
to each other...”
“Mental symptoms include: ’changeable mood; introspective; silently brooding. Melancholic, sad, tearful. Not
communicative. Sighing and sobbing. After shocks, grief, disappointment...”
Nolan 2009 Mixed ulcerative/atrophic lichen planus subtype inmajority, erosive/desquamative in 50 out of 124 participants
Piattelli 2007 Only 4/20 of participants had erosive/atrophic lichen planus. Results not reported separately. 1 erosive and 1
atrophic participant in each arm - very small number. Emphasis of paper on apoptotic process
Rajar 2008 Not randomised.Nodetails on randomisation or blinding. Text states that participants were “randomly divided
into two groups”. Participants not blinded as bases are difference (gel vs liquid paraffin). Author contacted
(uzmarajar@yahoo.com) 10 August 2010 and 29 August 2010 for clarification, but no response. Vulval LP. N
= 34. Only 82% had erosive subtype. Breakdown of results not available; hence, the study was excluded
Rödström 1994 Not randomised. No information on randomisation, allocation concealment, or blinding. States “patients
were chosen consecutively from those referred to or attending the Department”. Assume n = 20 in each arm
(not stated)
Baseline demographics and clinical data not published.
Results all expressed as a percentage change from baseline. No raw data published
Scardina 2006 Included participants with dysplasia and commented on whether dysplasia improved after treatment
No information on randomisation.
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Scheer 2006 Case series n = 5. Not a RCT.
Sieg 1995 Not erosive lichen planus (13 participants with chronic oral lichen planus)
Silver 1991 Not a RCT.
Thongprasom 2003 Not a RCT.
Thongprasom 2007 Oral lichen planus, not erosive.
Tyldesley 1977 No details on randomisation or allocation concealment.
No VAS.
No details on objective clinical assessment.
Not ITT.
No breakdown of baseline demographics in the 2 arms.
N = 18 for erosive subtype out of 23.
Ungphaiboon 2005 Compares triamcinolone acetonidemouthwash vs paste. No clear randomisation and blinding. Small numbers.
7/20 with erosive subtype. Outcome points not well-defined. Clinical response ranges for clinical scores too
wide, especially score 2 (34% to 99% reduction)
Wei 2003 Not a RCT.
Xia 2006 Self-controlled trial (split body-part) in ulcerative OLP. Exclusion criteria as per protocol
Xu 2002 Not ELP. No blinding, no allocation concealment. RCT.
Characteristics of studies awaiting assessment [ordered by study ID]
Agha-Hosseini 2010
Methods Randomised double-blind placebo-controlled trial
Participants 37 biopsy-proven symptomatic OLP participants
Interventions A: Purslane (n = 20)
B: Placebo (n = 17)
For 3 months
Outcomes Outcomes of the trial
1. Visual analogue scale (VAS) and clinical improvement including lesion type and size (assessments points = baseline,
after 2 weeks, and each month for 6 months)
Notes -
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Cilurzo 2010
Methods A double-blind, controlled study
Participants 3 groups of participants (n = 16) with OLP
Interventions A new mucoadhesive prolonged release tablet containing 24 mug clobetasol-17-propionate (CP) suitable for the
management of OLP
3 groups of participants (n = 16) received applications 3 times per day over 4 weeks of the developed clobetasol-17-
propionate (CP) tablets
A: Active treatment tablets (group CP-T)
B: Placebo tablets (group CP-P)
C: Commercial CP ointment for cutaneous application (123 mug/application) extemporary mixed with orabase
(group CP-O)
Outcomes Outcomes of the trial
1. Pain and ulceration
Notes -
Javadzadeh 2008
Methods Randomised, double-blind clinical trial
Participants 50 participants who matched the inclusion criteria
Interventions A: Experimental group - 5 ml of mouthwash 4 times per day for 5 minutes
B: Control group - dexamethasone tablet, nystatin drop, and diphenhydramine syrup
Outcomes Outcomes of the trial
1. Severity of the lesions and pain (assessment points = initial 1-, 2-, 4-, 8-, and 12-week intervals)
Notes -
Salazar-Sanchez 2010
Methods Randomised, double-blind study
Participants 64 participants with OLP
Interventions A: Topical application of aloe vera (AV) (n = 32)
B: Placebo (n = 32)
At a dose of 0.4 ml (70% concentration) 3 times per day
Outcomes Outcomes of the trial
1. Pain and quality of life (VAS for rating pain; clinical scale for scoring the lesions, the Oral Health Impact Profile
49 (OHIP-49), and the Hospital Anxiety-Depression (HAD) scale; assessment points after 6 and 12 weeks)
Notes -
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Wu 2010
Methods Prospective randomised, positive-control, double-blind clinical trial
Participants 69 participants with erosive OLP
Interventions A: Thalidomide 1% paste (n = 37)
B: Dexamethasone 0.043% paste (n = 32) for 1 week
Participants without erosions after initial 1-week treatment were followed for recurrence; whereas, those with ongoing
erosions received an additional 3-week treatment
Outcomes Outcomes of the trial
1. Size of erosive area
2. Visual analogue scale (VAS) scores
3. 3-month recurrence rates
4. Adverse effects at 1 year
Notes -
Xiong 2009
Methods Randomised controlled trial
Participants 56 OLP participants
Interventions Polysaccharide nucleic acid fraction of bacillus calmette-guerin (BCG-PSN) sieved out from various immunomod-
ulators to evaluate the short-term therapeutic efficacy and clinical safety of intralesional BCG-PSN injection for
erosive OLP
A: Intralesional injection of 0.5 ml BCG-PSN every other day (n = 31)
B: 10 mg triamcinolone acetonide (TA, a positive-controlled group, n = 25) every week for 2 weeks
After the cessation of treatment, those cured from erosion were followed up for 3 months
Outcomes Outcomes of the trial
1. Erosive areas and visual analogue scale (VAS) scores both at the start and the end of the treatment
2. Adverse reactions and the recurrence intervals were also registered
Notes -
Characteristics of ongoing studies [ordered by study ID]
NCT00135733
Trial name or title A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Efficacy and Safety of Alefacept in the
Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
(This study has been terminated. Pharmaceutical sponsor withdrew financial support)
Methods Allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
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NCT00135733 (Continued)
Masking: double-blind (subject, investigator, outcomes assessor)
Primary purpose: treatment
Participants Inclusion criteria of the trial
• At least 18 years of age
• Diagnosis of moderate to severe mucosal lichen planus
• No systemic (oral or injectable) treatment of lichen planus for 4 weeks prior to starting study drug
• Willing to forgo changes in topical treatment (creams) for 4 weeks before receiving the study drug and
during the course of the study
• Off of topical tacrolimus or pimecrolimus for 4 weeks prior to starting the study drug
• CD4+ T lymphocyte counts must be above the lower limit of normal laboratory value
Interventions Amevive (Alefacept) vs placebo
Outcomes Primary outcomes of the trial
• Statistically significant changes in pain level
• Statistically significant changes in appearance of lesions (sores)
Secondary outcomes of the trial
• Statistically significant changes in severity of itching
• Statistically significant changes in redness, amount of body surface area involved, number of sores,
and/or depth of involvement
• Statistically significant changes in quality of life
Starting date April 2004 - December 2004
Contact information Principal Investigator: Alexandra B. Kimball, MD,MPH, CURTIS - Clinical Unit for Research Trials in Skin
at Partners (MGH and BWH)
Notes -
NCT01061853
Trial name or title Efficacy of Topical Rapamycin in The Treatment of Chronic Erosive Oral Lichen Planus. Double Blind
Randomised Controlled Trial Rapamycin vs Topical Steroids
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: double-blind (subject, investigator)
Primary purpose: treatment
Participants Inclusion criteria of the trial
• 18 years to 85 years
• Oral lichen planus
• Oral erosive area more than 1 cm²
• Lichen planus pathologically proven
Interventions Topical sirolimus and petrolatum in orabase (Rapamune) 1 mg/ml bid 3 months vs topical betamethasone 0.
05% in orabase and Phosal (Diprolene) bid during 3 months
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NCT01061853 (Continued)
Outcomes Primary outcomes of the trial
• Complete clearing of oral erosive lesions (time frame: 3 months)
Secondary outcomes of the trial
• Regression of erosive surface area (time frame: 3 months)
Starting date February 2008 (expected completion date February 2013)
Contact information Loïc Vaillant, MD (+33(0)247479080, vaillant@med.univ-tours.fr); and Brigitte Hüttenberger, MD (+33
(0)247478347, b.huttenberger@chu-tours.fr)
Notes France
NCT01282515
Trial name or title A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative
Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP)
Methods Allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: single-blind (investigator)
Primary purpose: treatment
Participants Inclusion criteria of the trial
• 18 years and older
• Females with symptomatically genital ELP
• Clinically verified by at least one doctor from the Vulva clinic
• Untreated for ELP for at least 4 weeks
Interventions Hexaminolevulinate one PDT treatment vs continuous clobetasol propionate
Outcomes Primary outcomes of the trial
• Percentage change of GELP score and/or VAS score 6 weeks after start of treatment (time frame: 6
weeks)
Secondary outcomes of the trial
• Percentage change of GELP score and/or VAS score 6 months after start of treatment (time frame: 6
months)
Estimated enrolment: 48
Starting date August 2011 (expected completion date June 2012)
Contact information Anne LiseHelgesen, Candidate ofMedicine (0047 98634403, anneliseord@yahoo.no); TrondWarloe,Doctor
Medicinae (trond.warloe@radiumhospitalet.no)
Notes Rikshospitalet, Oslo University hospital
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NCT01375101
Trial name or title Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus
Methods Allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants Inclusion criteria of the trial
• 12 to 60 years
• Confirmation of clinical diagnosis of atrophic and erosive lichen planus by histological examination
• 2-week wash-out periods after the last treatment
• Atrophic and erosive lesion greater than 1 cm pain
• Burning greater than 3.5 in VAS Score
Interventions Quercetin (flavonoid with therapeutical anti-inflammatory and antioxidant action) vs placebo, both capsules
BD 1 month
Outcomes Primary outcomes of the trial
• The effects of this Drug on OLP measured with VAS scale for pain and evaluation of intensity of
lesions (time frame: 2 months)
(VAS used to evaluate pain, intensity of lesions recorded weekly, and any side-effects)
Starting date April 2010 (expected completion date July 2011)
Contact information Maryam Amirchaghmaghi, Assistant Professor (0098-0511889201, amirchakhmaghim@mums.ac.ir)
Notes Iran
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D A T A A N D A N A L Y S E S
Comparison 1. Pimecrolimus versus placebo/vehicle cream
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain reduction using visual
analogue scale (VAS)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 1% pimecrolimus cream
versus placebo (0 to 100 score)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 1% pimecrolimus versus
placebo (0 to 4 score for basal
pain)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 1% pimecrolimus versus
placebo (0 to 4 score for feeding
pain)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Physician Global Assessment:
Weighted sums of ulceration,
erythema and reticulation
(mm²)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 1% pimecrolimus versus
placebo
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Physician Global Assessment:
Surface of erosive lesions
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 1% pimecrolimus versus
placebo (0 to 4 score)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Physician Global Assessment 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Clinical response: Complete
clearance
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Clobetasol propionate versus active treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain reduction using visual
analogue scale (VAS)
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 0.025%
clobetasol-17-propionate vs
0.025% lipophilic ointment in
hydrophilic phase (0 to 100
score)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 0.05% clobetasol
propionate versus 5%
mesalazine gel (0 to 10 score)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.3 0.025% clobetasol
propionate versus 0.05%
clobetasol propionate (0 to 10
score)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Improvement in pain symptoms
by VAS (> = 50%)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 0.025% vs 0.05%
clobetasol propionate (no
symptoms versus partial or no
response)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Physician Global Assessment
(Thongprasom score)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 0.025%
clobetasol-17-propionate
versus 0.025% conventional
formulation
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 0.025% clobetasol
propionate versus 0.05%
clobetasol propionate
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Physician Global Assessment
(Thongprasom score)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 0.025% clobetasol
propionate versus 0.05%
clobetasol propionate
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. 0.1% Triamcinolone acetonide versus ciclosporin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain reduction using visual
analogue scale (VAS) (0 to 100
scale)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Physician Global Assessment
(Thongprasom score)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 4. 0.1% Tacrolimus versus 0.05% clobetasol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain reduction using the VAS (0
to 10 score)
1 Mean Difference (Fixed, 95% CI) Totals not selected
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Comparison 5. Aloe vera gel versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in pain symptoms
by VAS (> = 50%) (Complete
or good response versus poor or
no response)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Physician Global Assessment
(Thongprasom score)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 6. Ciclosporin versus active treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in pain symptoms
by VAS (> = 50%) (no
symptoms versus partial or no
response)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 1.5% Ciclosporin versus
0.025% clobetasol
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Physician Global Assessment
(Thongprasom score)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 1.5% ciclosporin versus
0.025% clobetasol propionate
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Physician Global Assessment:
Severity of disease
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Ciclosporin versus vehicle
(0 to 3 score)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Radix tripterygium hypoglaucum (THT) vs tripterygium glucosides (TGT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Physician Global Assessment:
Cure of erosive lesions
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Grade I lesions 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Grade II lesions 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 8. Flucinonide vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Physician Global Assessment:
Clinical signs (Complete vs
good, partial, or no response)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 9. Betamethasone versus 0.1% triamcinolone acetonide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Physician Global Assessment:
Clinical severity (0 to 12 score)
1 Mean Difference (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Pimecrolimus versus placebo/vehicle cream, Outcome 1 Pain reduction using
visual analogue scale (VAS).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 1 Pimecrolimus versus placebo/vehicle cream
Outcome: 1 Pain reduction using visual analogue scale (VAS)
Study or subgroup 1% pimecrolimus Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1% pimecrolimus cream versus placebo (0 to 100 score)
Swift 2005 10 20.75 (22.28) 10 24.05 (15.77) -3.30 [ -20.22, 13.62 ]
2 1% pimecrolimus versus placebo (0 to 4 score for basal pain)
Passeron 2007 6 0.83 (0.98) 6 0.67 (0.82) 0.16 [ -0.86, 1.18 ]
3 1% pimecrolimus versus placebo (0 to 4 score for feeding pain)
Passeron 2007 6 1.67 (1.63) 6 1.33 (1.37) 0.34 [ -1.36, 2.04 ]
-50 -25 0 25 50
Favours 1% pimecrolimus Favours placebo
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Analysis 1.2. Comparison 1 Pimecrolimus versus placebo/vehicle cream, Outcome 2 Physician Global
Assessment: Weighted sums of ulceration, erythema and reticulation (mm²).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 1 Pimecrolimus versus placebo/vehicle cream
Outcome: 2 Physician Global Assessment: Weighted sums of ulceration, erythema and reticulation (mm2)
Study or subgroup 1% pimecrolimus Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1% pimecrolimus versus placebo
Swift 2005 10 120.79 (60.92) 10 177.36 (109.11) -56.57 [ -134.02, 20.88 ]
-100 -50 0 50 100
Favours 1% pimecrolimus Favours placebo
Analysis 1.3. Comparison 1 Pimecrolimus versus placebo/vehicle cream, Outcome 3 Physician Global
Assessment: Surface of erosive lesions.
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 1 Pimecrolimus versus placebo/vehicle cream
Outcome: 3 Physician Global Assessment: Surface of erosive lesions
Study or subgroup 1% pimecrolimus Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1% pimecrolimus versus placebo (0 to 4 score)
Passeron 2007 6 0.83 (0.98) 6 1.33 (0.52) -0.50 [ -1.39, 0.39 ]
-4 -2 0 2 4
Favours 1% pimecrolimus Favours placebo
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Analysis 1.4. Comparison 1 Pimecrolimus versus placebo/vehicle cream, Outcome 4 Physician Global
Assessment.
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 1 Pimecrolimus versus placebo/vehicle cream
Outcome: 4 Physician Global Assessment
Study or subgroup
1% pime-
crolimus
cream Vehicle cream Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Volz 2008 7/10 1/10 7.00 [ 1.04, 46.95 ]
0.2 0.5 1 2 5
Favours vehicle Favours 1% pimecrolimus
Analysis 1.5. Comparison 1 Pimecrolimus versus placebo/vehicle cream, Outcome 5 Clinical response:
Complete clearance.
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 1 Pimecrolimus versus placebo/vehicle cream
Outcome: 5 Clinical response: Complete clearance
Study or subgroup
1% pime-
crolimus
cream Vehicle cream Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Volz 2008 7/10 2/10 3.50 [ 0.95, 12.90 ]
0.2 0.5 1 2 5
Favours vehicle Favours 1% pimecrolimus
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Analysis 2.1. Comparison 2 Clobetasol propionate versus active treatment, Outcome 1 Pain reduction
using visual analogue scale (VAS).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 2 Clobetasol propionate versus active treatment
Outcome: 1 Pain reduction using visual analogue scale (VAS)
Study or subgroup Clobetasol Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 0.025% clobetasol-17-propionate vs 0.025% lipophilic ointment in hydrophilic phase (0 to 100 score)
Campisi 2004 18 9.4 (10.2) 27 27.7 (24.2) -18.30 [ -28.57, -8.03 ]
2 0.05% clobetasol propionate versus 5% mesalazine gel (0 to 10 score)
Sardella 1998 6 2 (3.16) 6 2.83 (2.64) -0.83 [ -4.12, 2.46 ]
3 0.025% clobetasol propionate versus 0.05% clobetasol propionate (0 to 10 score)
Carbone 2009 15 0.87 (1.51) 15 1.13 (1.73) -0.26 [ -1.42, 0.90 ]
-50 -25 0 25 50
Favours clobetasol Favours control
Analysis 2.2. Comparison 2 Clobetasol propionate versus active treatment, Outcome 2 Improvement in
pain symptoms by VAS (> = 50%).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 2 Clobetasol propionate versus active treatment
Outcome: 2 Improvement in pain symptoms by VAS (> = 50%)
Study or subgroup 0.025% clobetasol 0.05% clobetasol Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0.025% vs 0.05% clobetasol propionate (no symptoms versus partial or no response)
Carbone 2009 8/15 9/15 0.89 [ 0.47, 1.67 ]
0.05 0.2 1 5 20
Favours 0.05% clobetasol Favours 0.025% clobetasol
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Analysis 2.3. Comparison 2 Clobetasol propionate versus active treatment, Outcome 3 Physician Global
Assessment (Thongprasom score).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 2 Clobetasol propionate versus active treatment
Outcome: 3 Physician Global Assessment (Thongprasom score)
Study or subgroup 0.025% clobetasol Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 0.025% clobetasol-17-propionate versus 0.025% conventional formulation
Campisi 2004 18 1.1 (0.9) 27 1.1 (1.2) 0.0 [ -0.61, 0.61 ]
2 0.025% clobetasol propionate versus 0.05% clobetasol propionate
Carbone 2009 15 2.27 (1.03) 15 1.8 (1.01) 0.47 [ -0.26, 1.20 ]
-2 -1 0 1 2
Favours 0.025% clobetasol Favours control
Analysis 2.4. Comparison 2 Clobetasol propionate versus active treatment, Outcome 4 Physician Global
Assessment (Thongprasom score).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 2 Clobetasol propionate versus active treatment
Outcome: 4 Physician Global Assessment (Thongprasom score)
Study or subgroup 0.025% clobetasol 0.05% clobetasol Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0.025% clobetasol propionate versus 0.05% clobetasol propionate
Carbone 2009 8/15 7/15 1.14 [ 0.56, 2.35 ]
0.02 0.1 1 10 50
Favours 0.05% clobetasol Favours 0.025% clobetasol
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Analysis 3.1. Comparison 3 0.1% Triamcinolone acetonide versus ciclosporin, Outcome 1 Pain reduction
using visual analogue scale (VAS) (0 to 100 scale).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 3 0.1% Triamcinolone acetonide versus ciclosporin
Outcome: 1 Pain reduction using visual analogue scale (VAS) (0 to 100 scale)
Study or subgroup
Triamcinolone
acetonide Ciclosporin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Yoke 2006 2 59.5 (23.33) 9 14.33 (25.71) 45.17 [ 8.73, 81.61 ]
-50 -25 0 25 50
Favours triamcinolone Favours ciclosporin
Analysis 3.2. Comparison 3 0.1% Triamcinolone acetonide versus ciclosporin, Outcome 2 Physician Global
Assessment (Thongprasom score).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 3 0.1% Triamcinolone acetonide versus ciclosporin
Outcome: 2 Physician Global Assessment (Thongprasom score)
Study or subgroup Triamcinolone Ciclosporin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Yoke 2006 2 3.5 (0.707) 9 2.89 (1.537) 0.61 [ -0.79, 2.01 ]
-2 -1 0 1 2
Favours triamcinolone Favours ciclosporin
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Analysis 4.1. Comparison 4 0.1% Tacrolimus versus 0.05% clobetasol, Outcome 1 Pain reduction using the
VAS (0 to 10 score).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 4 0.1% Tacrolimus versus 0.05% clobetasol
Outcome: 1 Pain reduction using the VAS (0 to 10 score)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Radfar 2008 -0.639 (0.647) -0.64 [ -1.91, 0.63 ]
-4 -2 0 2 4
Favours 0.1% tacrolimus Favours 0.05% clobetasol
Analysis 5.1. Comparison 5 Aloe vera gel versus placebo, Outcome 1 Improvement in pain symptoms by
VAS (> = 50%) (Complete or good response versus poor or no response).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 5 Aloe vera gel versus placebo
Outcome: 1 Improvement in pain symptoms by VAS (> = 50%) (Complete or good response versus poor or no response)
Study or subgroup Aloe vera gel Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choonhakarn 2008 24/24 3/21 6.16 [ 2.35, 16.13 ]
0.05 0.2 1 5 20
Favours placebo Favours aloe vera gel
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Analysis 5.2. Comparison 5 Aloe vera gel versus placebo, Outcome 2 Physician Global Assessment
(Thongprasom score).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 5 Aloe vera gel versus placebo
Outcome: 2 Physician Global Assessment (Thongprasom score)
Study or subgroup Aloe vera gel Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choonhakarn 2008 1/24 0/21 2.64 [ 0.11, 61.54 ]
0.02 0.1 1 10 50
Favours placebo Favours aloe vera gel
Analysis 6.1. Comparison 6 Ciclosporin versus active treatment, Outcome 1 Improvement in pain
symptoms by VAS (> = 50%) (no symptoms versus partial or no response).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 6 Ciclosporin versus active treatment
Outcome: 1 Improvement in pain symptoms by VAS (> = 50%) (no symptoms versus partial or no response)
Study or subgroup 1.5% ciclosporin 0.025% clobetasol Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1.5% Ciclosporin versus 0.025% clobetasol
Conrotto 2006 4/20 8/19 0.48 [ 0.17, 1.32 ]
0.05 0.2 1 5 20
Favours 0.025% clobetasol Favours 1.5% ciclosporin
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Analysis 6.2. Comparison 6 Ciclosporin versus active treatment, Outcome 2 Physician Global Assessment
(Thongprasom score).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 6 Ciclosporin versus active treatment
Outcome: 2 Physician Global Assessment (Thongprasom score)
Study or subgroup 1.5% ciclosporin 0.025% clobetasol Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 1.5% ciclosporin versus 0.025% clobetasol propionate
Conrotto 2006 9/19 3/20 3.16 [ 1.00, 9.93 ]
0.02 0.1 1 10 50
Favours 0.025% clobetasol Favours 1.5% ciclosporin
Analysis 6.3. Comparison 6 Ciclosporin versus active treatment, Outcome 3 Physician Global Assessment:
Severity of disease.
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 6 Ciclosporin versus active treatment
Outcome: 3 Physician Global Assessment: Severity of disease
Study or subgroup Ciclosporin Vehicle
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ciclosporin versus vehicle (0 to 3 score)
Eisen 1990 5 0.3 (0.1) 3 1.7 (0.4) -1.40 [ -1.86, -0.94 ]
-4 -2 0 2 4
Favours ciclosporin Favours vehicle
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Analysis 7.1. Comparison 7 Radix tripterygium hypoglaucum (THT) vs tripterygium glucosides (TGT),
Outcome 1 Physician Global Assessment: Cure of erosive lesions.
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 7 Radix tripterygium hypoglaucum (THT) vs tripterygium glucosides (TGT)
Outcome: 1 Physician Global Assessment: Cure of erosive lesions
Study or subgroup Radix THT TGT Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Grade I lesions
Lin 2005 6/21 11/21 0.55 [ 0.25, 1.20 ]
2 Grade II lesions
Lin 2005 11/26 15/26 0.73 [ 0.42, 1.28 ]
0.1 0.2 0.5 1 2 5 10
Favours TGT Favours Radix THT
Analysis 8.1. Comparison 8 Flucinonide vs placebo, Outcome 1 Physician Global Assessment: Clinical signs
(Complete vs good, partial, or no response).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 8 Flucinonide vs placebo
Outcome: 1 Physician Global Assessment: Clinical signs (Complete vs good, partial, or no response)
Study or subgroup Flucinonide Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Voute 1993 2/14 0/13 4.67 [ 0.24, 88.96 ]
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours flucinonide
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Analysis 9.1. Comparison 9 Betamethasone versus 0.1% triamcinolone acetonide, Outcome 1 Physician
Global Assessment: Clinical severity (0 to 12 score).
Review: Interventions for erosive lichen planus affecting mucosal sites
Comparison: 9 Betamethasone versus 0.1% triamcinolone acetonide
Outcome: 1 Physician Global Assessment: Clinical severity (0 to 12 score)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Malhotra 2008 1.78 (0.8215) 1.78 [ 0.17, 3.39 ]
-10 -5 0 5 10
Favours betamethasone Favours triamcinolone
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Table 1. Summary of included studies
Inter-
vention
1
Inter-
vention
2
Fre-
quency
Treat-
ment
Dura-
tion
Assess-
ment
Points
*Method
of Di-
agnosis
Oral or
Genital
Total
Ran-
domised
All Ero-
sive?
ELP
Ran-
domised
Re-
ported
Results
1
Passeron
2007
1%
Pime-
crolimus
cream
Placebo BD 4 weeks Week 0,
4, and 8
Histol-
ogy and
clinical
Oral 12 Yes 12 1%
Pime-
crolimus
cream
effective
com-
pared
with
placebo
2 Swift
2005
1%
Pime-
crolimus
cream
Placebo BD 4 weeks Week 0,
2, and 4
Histol-
ogy and
clinical
Oral 20 Yes 20 Signif-
icant re-
duc-
tion in
VAS (P
=0.022)
in treat-
ment
group,
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Table 1. Summary of included studies (Continued)
but not
lesion
size
3 Volz
2008
1%
Pime-
crolimus
cream
Placebo BD 30 days Day 0,
30, and
60
Histol-
ogy and
clinical
Oral 20 Yes 20 Signif-
icant re-
duc-
tion in
Investi-
gator
Global
Assess-
ment (P
=0.032)
in treat-
ment
group
4 Camp-
isi
2004
Clobe-
tasol-
17-pro-
pionate
lipid-
loaded
micro-
spheres
0.025%
Con-
ven-
tional
lipophilic
oint-
ment
in hy-
drophilic
phase 0.
025%
BD for
1
month
then
once
daily
2
months
Month
0, 1,
and 7
Histol-
ogy and
clinical
Oral 50 Yes 50 No sig-
nifi-
cant dif-
ference
5 Car-
bone
2009
Top-
ical clo-
betasol
propi-
onate 0.
025%
Top-
ical clo-
betasol
propi-
onate 0.
05%
BD 2
months
Week 0,
2, 4, 6,
8, and
16
Histol-
ogy and
clinical
(WHO)
Oral 35 Yes 35 No sig-
nifi-
cant dif-
ference
6 Radfar
2008
Topical
tacrolimus
0.1%
oint-
ment
Top-
ical clo-
betasol
0.05%
oint-
ment
QDS 2/
52 -
TDS 2/
52 - BD
1/52
- OD 1/
52
6 weeks Week 0,
2, and 6
Histol-
ogy and
clinical
Oral 29 Yes 29 No sig-
nifi-
cant dif-
ference
7 Con-
rotto
2006
Topical
ci-
closporin
1.5%
gel
Top-
ical clo-
betasol
0.025%
gel
BD 2
months
Fort-
nightly
for 4
months
Histol-
ogy and
clinical
(WHO)
Oral 40 Yes 40 Topical
clobe-
tasol
signif-
icantly
65Interventions for erosive lichen planus affecting mucosal sites (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary of included studies (Continued)
better in
induc-
ing a
clinical
im-
prove-
ment,
but no
differ-
ence
in im-
proving
symp-
toms
8 Hegarty
2002
Flutica-
s-
one pro-
pionate
spray 2
puffs
Be-
tametha-
sone
sodium
phos-
phate
mouth-
wash
4 times
per day
14
weeks
(cross-
over; 2-
week
wash-
out)
Week
3, 6, 11,
and 14
Histol-
ogy and
clinical
Oral 44 Yes 44 At
Week
6 fluti-
casone
spray
was
signif-
icantly
better
in re-
ducing
clinical
signs
and
pain,
but no
differ-
ence in
VAS or
QoL
9 Lin
2005
Radix
triptery-
gium
hy-
poglau-
cum
tablet
(THT)
Triptery-
gium
gluco-
sides
tablet
(TGT)
THT -
5 tablets
TDS
TGT -
1.0 to 1.
5 mg/kg
TDS
Taper
dose af-
ter 2 to
4 weeks
3
months
Month
0 and 3
Histol-
ogy and
clinical
Oral 94 Yes 94 TGT
superior
to THT
in re-
ducing
clinical
sever-
ity (P =
0.043)
Subto-
tal
344 Subto-
tal
344
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Table 1. Summary of included studies (Continued)
10
Choonhakarn
2008
Aloe
vera gel
Placebo BD 8 weeks Week 0,
2, 4, 6,
and 8
Histol-
ogy and
clinical
Oral 54 No 45 Unable
to com-
ment
11 Eisen
1990
Ci-
closporin
rinse
Placebo TDS 8 weeks Week 0,
2, 4, 6,
and 8
Histol-
ogy and
clinical
Oral 16 No 8 Unable
to com-
ment
12 Voute
1993
Fluoci-
nonide
in adhe-
sive base
Placebo At least
6 times
daily
9 weeks Week 0,
3, and
9; and
month
5 to 19
Histol-
ogy and
clinical
Oral 40 No 27 Unable
to com-
ment
13 Malho-
tra
2008
Be-
tametha-
sone
oral
mini-
pulse
therapy
Topical
triamci-
nolone
ace-
tonide
0.1%
paste
Be-
tametha-
sone -
5 mg
2 days/
week
Triam-
ci-
nolone -
TDS
Both for
3
months,
then ta-
per dose
6
months
Week 0,
2, 4, 8,
16, 20,
and 24
Clinical
only
Oral 49 No 22 Unable
to com-
ment
14 Sardella
1998
Clobe-
ta-
sol pro-
pionate
oint-
ment 0.
05%
5%
Topical
mesalazine
gel in
adhe-
sive
base
BD 4 weeks Week 0
and 4
Histol-
ogy and
clinical
(WHO)
Oral 25 No 12 Unable
to com-
ment
15 Yoke
2006
Triam-
ci-
nolone
ace-
tonide
in
orabase
Ci-
closporin
solution
TDS 8 weeks Week 0,
2, 4,
and 8;
and
month
3, 6, 9,
and 12
Histol-
ogy and
clinical
Oral 139 No 15 Unable
to com-
ment
Subto-
tal
323 Subto-
tal
129
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Table 1. Summary of included studies (Continued)
Total 667 Total 473
*Histology - Histological features consistent with mucosal LP
Clinical - clinical features consistent with mucosal LP
WHO - Clinical features based on 1978 WHO criteria for oral precancerous lesions
Table 2. Severity Tools Used for Primary Outcomes
Study Clinical Severity Symptoms
1 Passeron 2007 Surface area ordinal scale 1 to 4 Pain (basal and during feeding, visual scale 0 to 4)
2 Swift 2005 Clinical score (weighted sums of ulceration mm2,
erythema mm2, reticulation mm2)
VAS 0 to 100
3 Volz 2008 Erosive surface area ordinal scale of 1 to 4 (< 5%
= 1, 5% to 15% = 2, > 15% to 25% = 3, > 25% =
4)
Investigator Global Assessment on a 5-point scale
was determined at day 30 by qualifying the overall
status of the oral mucosa in comparison with base-
line
VAS 0 to 10 (continuous and food-triggered pain)
NB a composite score (made of erosive surface area
and VAS) was reported
4 Campisi 2004 Clinical score 0 to 5 (Thongprasom 1992) VAS 0 to 100
5 Carbone 2009 Clinical score 0 to 5 (Thongprasom 1992) VAS 0 to 100
6 Radfar 2008 Mean lesion size VAS 0 to 10
7 Conrotto 2006 Clinical score 0 to 5 (Thongprasom 1992) VAS 0 to 10
8 Hegarty 2002 Clinical score 0 to 5 (Thongprasom 1992)
Mean surface area
1. VAS 0 to 100
2. McGill pain score
9 Lin 2005 Clinical severity
Participants divided into Grade I (erosive and ul-
cerative lesions) or Grade II (erosive lesions only)
Response reported, subdivided into 3 categories
(cured completely, effective, ineffective)
None
10 Choonhakarn 2008 Clinical score 0 to 5 (Thongprasom 1992) VAS 0 to 10
11 Eisen 1990 Clinical score (0 to 3) Symptom score (0 to 3)
12 Voute 1993 Clinical severity measured by comparing clinical
photographs.Only response reported, subdivided
into 5 categories
VAS (scale not stated)
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Table 2. Severity Tools Used for Primary Outcomes (Continued)
13 Malhotra 2008 Clinical score (semiquantitative system 0 to 12
based on site, area, and presence of erosions)
None
14 Sardella 1998 None VAS 0 to 10
15 Yoke 2006 Clinical score 0 to 5 (Thongprasom 1992) VAS 0 to 100
Table 3. Side-effects
Study Intervention 1 Intervention 2 Side-effects
1 Passeron 2007 1% pimecrolimus cream Placebo Pimecrolimus well-tolerated,
transient burning (2) during 1st
2 weeks
2 Swift 2005 1% pimecrolimus cream Placebo Pimecrolimus: slight burning tip
of tongue after applying 1%
pimecrolimus on gingiva lesions.
Resolved within minutes
3 Volz 2008 1% pimecrolimus cream Placebo Pimecrolimus: burning sensation
(4) and mucosal paraesthesia (1)
Placebo: burning sensation (1)
and mucosal paraesthesia (1)
4 Campisi 2004 Clobetasol-17-propionate lipid-
loaded micro-spheres 0.025%
Conventional lipophilic oint-
ment in hydrophilic phase 0.
025%
Oral candidiasis (1 in lipid-
loaded microspheres group, 2 in
conventional ointment group)
5 Carbone 2009 Topical clobetasol propionate 0.
025%
Topical clobetasol propionate 0.
05%
No side-effects
6 Radfar 2008 Topical tacrolimus 0.1% oint-
ment
Topical clobetasol 0.05% oint-
ment
Burning sensation with topical
tacrolimus
7 Conrotto 2006 Topical ciclosporin 1.5% gel Topical clobetasol 0.025% gel Ciclosporin: skin rashes (2),
parotid swelling (1), and dyspep-
sia (3)
Clobetasol: dyspepsia (1)
8 Hegarty 2002 Fluticasone propionate spray, 2
puffs
Betamethasone sodium phos-
phate mouthwash
Nausea (4); swollen mouth (1)
; bad taste and smell (6); dif-
ficulty in spray application (7);
dry mouth (2); sore throat (1);
red, painful tongue (1); and pseu-
domembranous candidiasis (1)
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Table 3. Side-effects (Continued)
9 Lin 2005 Radix tripterygium hypoglau-
cum tablet (THT)
Tripterygium glucosides tablet
(TGT)
TGT - menstrual disturbance (6)
and leucopenia (1)
10 Choonhakarn 2008 Aloe vera gel Placebo No serious side-effects. 2 receiv-
ing aloe vera gel reported stinging
and mild itching at lesions within
1st week, but symptoms sponta-
neously disappeared with contin-
ued use
11 Eisen 1990 Ciclosporin rinse Placebo No adverse side-effects. Transient
burning sensationofmucosal sur-
faces during swishing of medica-
tion reported in all participants
12 Voute 1993 Fluocinonide in adhesive base Placebo No side-effects during study and
follow-up period
13 Malhotra 2008 Betamethasone oral mini-pulse
therapy
Topical triamcinolone acetonide
0.1% paste
Betamethasone: oedema over face
(transient) (7), oedema over
hands and feet (4), epigastric dis-
comfort (7), weakness/fatigue (5)
, loose stools (1), headache (1),
diabetes mellitus (1), weight gain
(1), and dry mouth (1)
Triamcinolone: epigastric dis-
comfort (1) and candidiasis (5)
14 Sardella 1998 Clobetasol propionate ointment
0.05%
5% Topical mesalazine gel in ad-
hesive base
No side-effects
15 Yoke 2006 Triamcinolone acetonide in
orabase
Ciclosporin solution No significant
adverse events. Transient burning
sensation upon initial application
with both treatments
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A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library) search strategy
#1((eros* or vulva* or oral or ulcerated or mucos*) and (lichen and planus))
#2MeSH descriptor Lichen Planus explode all trees
#3(lichen planus)
#4(#1 OR #2 OR #3)
Appendix 2. MEDLINE (OVID) search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (human and animals)).sh.
10. 8 not 9
11. erosive lichen planus.mp.
12. Lichen planus.mp. or exp Lichen Planus/
13. vulval lichen planus.mp.
14. vulvar lichen planus.mp.
15. oral erosive lichen planus.mp.
16. ulcerated lichen planus.mp.
17. mucosal lichen planus.mp.
18. 11 or 16 or 13 or 17 or 12 or 15 or 14
19. 18 and 10
Appendix 3. EMBASE (OVID) search strategy
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. erosive lichen planus.mp.
15. Lichen planus.mp. or exp Lichen Planus/
16. vulval lichen planus.mp.
17. vulvar lichen planus.mp.
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18. oral erosive lichen planus.mp.
19. ulcerated lichen planus.mp.
20. mucosal lichen planus.mp.
21. 14 or 19 or 16 or 20 or 15 or 18 or 17
22. 21 and 13
Appendix 4. LILACS search strategy
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
ORMHDOGS ORMH RABBITS ORMH SWINE) ANDNOT (CT HUMAN AND CT ANIMALS)) [Words] and (lichen and
planus) or (liquen and plano) [Words]
WH A T ’ S N E W
Last assessed as up-to-date: 15 June 2009.
Date Event Description
16 May 2012 Amended Reference has been made to the updated Cochrane review on “Interventions for Oral Lichen Planus”
(Thongprasom 2011)
Minor amendments have been made to the Abstract and the Plain Language Summary
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Analysing the data: J Leonardi-Bee
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There were minor updates to the background section.
We did not collect data on adverse events from interventions for erosive lichen planus by running separate searches looking specifically
for adverse effects of treatments used. This was an over-ambitious goal and an under-estimation of the extensive search required to fulfil
this.
We added in a secondary outcome (j) reduction in target/mean lesion size (for oral lesions), which was measured by two studies.
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Medical Subject Headings (MeSH)
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